
==== Front
ASN NeuroASN NeuroASNspasnASN NEURO1759-0914SAGE Publications Sage CA: Los Angeles, CA 10.1177/175909141985554110.1177_1759091419855541Special Collection on Neurodegenerative DiseasesReviewAmyloid Beta-Related Alterations to Glutamate Signaling Dynamics
During Alzheimer’s Disease Progression Findley Caleigh A. 12Bartke Andrzej 3https://orcid.org/0000-0001-6604-1874Hascup Kevin N. 124https://orcid.org/0000-0003-1037-0809Hascup Erin R. 12
1 Department of Neurology, Center for Alzheimer’s Disease and
Related Disorders, Neuroscience Institute, Southern Illinois University School
of Medicine, Springfield, IL, USA
2 Department of Pharmacology, Southern Illinois University School
of Medicine, Springfield, IL, USA
3 Department of Internal Medicine, Southern Illinois University
School of Medicine, Springfield, IL, USA
4 Department of Molecular Biology, Microbiology &
Biochemistry, Southern Illinois University School of Medicine, Springfield, IL,
USAErin R. Hascup, Department of Neurology,
Center for Alzheimer’s Disease and Related Disorders, Neuroscience Institute,
Southern Illinois University School of Medicine, P.O. Box 19628, Springfield, IL
62794-9628, USA. Email: ehascup@siumed.edu18 6 2019 Jan-Dec 2019 11 175909141985554129 3 2019 10 5 2019 14 5 2019 © The Author(s) 20192019SAGE PublicationsCreative Commons Non Commercial CC BY-NC: This article is distributed
under the terms of the Creative Commons Attribution-NonCommercial 4.0
License (http://www.creativecommons.org/licenses/by-nc/4.0/) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Alzheimer’s disease (AD) ranks sixth on the Centers for Disease Control and
Prevention Top 10 Leading Causes of Death list for 2016, and
the Alzheimer’s Association attributes 60% to 80% of dementia cases as AD
related. AD pathology hallmarks include accumulation of senile plaques and
neurofibrillary tangles; however, evidence supports that soluble amyloid beta
(Aβ), rather than insoluble plaques, may instigate synaptic failure. Soluble Aβ
accumulation results in depression of long-term potentiation leading to
cognitive deficits commonly characterized in AD. The mechanisms through which Aβ
incites cognitive decline have been extensively explored, with a growing body of
evidence pointing to modulation of the glutamatergic system. The period of
glutamatergic hypoactivation observed alongside long-term potentiation
depression and cognitive deficits in later disease stages may be the consequence
of a preceding period of increased glutamatergic activity. This review will
explore the Aβ-related changes to the tripartite glutamate synapse resulting in
altered cell signaling throughout disease progression, ultimately culminating in
oxidative stress, synaptic dysfunction, and neuronal loss.

α7 nicotinic acetylcholine receptors (α7nAChRs)amyloid oligomerssynaptic dysfunctionexcitotoxicitymild cognitive impairmentN-methyl-D-aspartic acid (NMDA)National Institute on Aginghttp://doi.org/10.13039/100000049R01AG057767R01AG061937American Diabetes Associationhttp://doi.org/10.13039/1000000411-19-IBS-126Illinois Department of Public Healthhttp://doi.org/10.13039/10000488863282003Dcover-dateJanuary-December 2019
==== Body
Introduction
The glutamatergic synapse, referred to as the tripartite synapse, involves three
elements: presynaptic neurons, postsynaptic neurons, and astrocytes. There are
several different synaptic components expressed on both neurons and astrocytes in
the glutamate synapse, as summarized in Table 1. These components include two types
of glutamate receptors that exist on these synaptic elements: metabotropic and
ionotropic. Metabotropic glutamate receptors (mGluRs) are present on both
presynaptic and postsynaptic neurons (Revett et al., 2013) and involve three
different groups of receptors: Group I (mGluR1 and mGluR5), Group II (mGluR 2 and
3), and Group III (mGluR4, mGluR6, mGluR7, and mGluR8; Petralia et al., 1996; Rudy et al., 2015). Group
I mGluRs are Gq-coupled and are expressed postsynaptically, depolarizing the
postsynaptic neuron upon stimulation (Petralia et al., 1996; Ferraguti and Shigemoto,
2006; Revett et al.,
2013). Groups II and III mGluRs are Gi/o-coupled inhibitory autoreceptors
and are expressed both pre- and postsynaptically (Petralia et al., 1996; Rudy et al., 2015),
leading to inhibition of presynaptic glutamate release or postsynaptic excitation
(Ambrosini et al.,
1995; Ferraguti and
Shigemoto, 2006).

Table 1. Brief Overview of Glutamatergic Synapse Components: Localization and
Function.

Glutamate synapse components	Localization	Function	References	
VGluT	Presynaptic neuron	Packaging glutamate into vesicles	Takamori
et al., 2000; Fremeau et al., 2001, 2004	
Glutaminase	Presynaptic neuron	Synthesizes glutamate from glutamine	
Revett
et al., 2013
	
α7nAChR	Both neurons and glia	Soluble Aβ binding (in low concentrations) triggers
Ca2+-dependent release of glutamate from the
presynaptic neuron, as well as stimulation of the postsynaptic
neuron	Wang
et al., 2000b; Gahring et al., 2004;
Magdesian et al., 2005; Puzzo et al., 2008;
Mura
et al., 2012;Hascup and Hascup,
2016	
mGluR Group II/III	Pre- and postsynaptic neuron	Gi/o-coupled receptor, inhibition of presynaptic release of
glutamate or inhibition of postsynaptic response to
stimulation	Ambrosini
et al., 1995; Petralia et al., 1996;
Ferraguti and Shigemoto, 2006; Rudy et al., 2015	
mGluR Group I	Postsynaptic neuron	Gq-coupled receptor, depolarizes neuron upon binding of
glutamate and results in Ca2+ release from
intracellular stores	Petralia
et al., 1996; Ferraguti and Shigemoto,
2006; Revett et al.,
2013	
AMPA	Pre- and postsynaptic neuron	Presynaptically promotes the formation of synapses.
Postsynaptically depolarizes the neuron upon glutamate
binding	Wisden and
Seeburg, 1993; Isaac et al., 2007;
Rudy
et al., 2015	
NMDA	Postsynaptic neuron	Contains a magnesium block that is removed upon depolarization
of postsynaptic membrane, allowing for Ca2+ influx
into the neuron	Calabresi
et al., 1992; Wisden and Seeburg,
1993; Pandis et al., 2006;
Parsons
et al., 2007; Rudy et al., 2015	
GLT-1 (EAAT1)/GLAST (EAAT2)	Astrocytes	Clearance of glutamate from the synapse by uptake into
astrocytes	Lehre
et al., 1995; Revett et al.,
2013	
GS	Astrocytes	Conversion of glutamate to glutamine so that it may be
transported back to the presynaptic neuron	Norenberg
and Martinez-Hernandez, 1979; Parsons et al., 2007;
Revett
et al., 2013	
Note. Outline of glutamate neuronal and astrocytic
components and their functions in glutamatergic neurotransmission.

α7nAChR = alpha-7 nicotinic acetylcholine receptor;
AMPA = α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid;
EAAT = excitatory amino acid transporter; GLAST = glutamate aspartate
transporter; GLT-1 = glutamate transporter-1; GS = glutamine synthetase;
mGluR = metabotropic glutamate receptor;
NMDA = N-methyl-D-aspartic acid;
VGluT = vesicular glutamate transporter.

The ionotropic glutamate receptors are expressed both pre- and postsynaptically
(Wisden and Seeburg,
1993; Rudy et al.,
2015) and include α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
receptors (AMPAR), N-methyl-D-aspartic acid
receptors (NMDAR), and kainate receptors. AMPARs function presynaptically to promote
synapse and spine formation (Isaac et al., 2007). On the postsynaptic side, all three ionotropic
receptors are expressed (Wisden and Seeburg, 1993; Rudy et al., 2015). AMPARs are bound by
glutamate and lead to membrane depolarization, while NMDARs have a magnesium block
which is released upon membrane depolarization. This results from either
high-frequency stimulation inducing Na+ influx through AMPARs or
disinhibition of GABAergic synapses (Parsons et al., 2007), which then opens
the NMDAR ion channel (Calabresi
et al., 1992; Pandis
et al., 2006; Parsons et al., 2007). In fact, AMPARs and NMDARs are colocalized on the
postsynaptic membrane because of the cooperation required between the two receptors
in response to membrane depolarization (Takumi et al., 1999; Antal et al., 2008). The opening of NMDARs
results in Ca2+ influx into the postsynaptic neuron and, along with Group
I mGluRs, increases intracellular Ca2+ (Chen et al., 2002; Hardingham et al., 2002; Hardingham and Bading,
2003; Verkhratsky and
Kirchhoff, 2007; Yamin, 2009; Zhang
et al., 2016). NMDA interacts with glutamate such that the NR2 subunit of
the NMDA receptor binds glutamate, with NR2A and NR2B subtypes mediating
excitotoxicity in cultured cortical neurons (von Engelhardt et al., 2007). The NR2
subunit is expressed both synaptically (NR2A) and extrasynaptically (NR2B; Rudy et al., 2015).
Extrasynaptic NMDARs (E-NMDARS) are activated only by high concentrations of
glutamate, unlike synaptic NMDARs (S-NMDARS) that are located closer to the synaptic
cleft and are activated by presynaptic glutamate release (Groc et al., 2009; Newpher and Ehlers, 2009; Rudy et al., 2015). Both
E-NMDAR stimulation and NMDA/mGluR-mediated Ca2+ influx constitute
important factors in soluble amyloid beta (Aβ)-mediated neurotoxicity as explored
further in this review.

Glutamate is synthesized from glutamine by glutaminase in the presynaptic neuron
(Revett et al.,
2013), and then transported to the synaptic terminals where vesicular
glutamate transporter-1/2 (VGluT-1/2) packages glutamate into vesicles, which
release glutamate upon neuronal depolarization (Takamori et al., 2000; Fremeau
et al., 2001, 2004). Glutamate clearance from the synapse is carried out
through high-efficiency excitatory amino acid transporters (EAATs) located primarily
on astrocytes. Glutamate transporter-1 (GLT-1) and glutamate aspartate transporter
(GLAST) allow for uptake of glutamate into astrocytes (Lehre et al., 1995), where glutamate is
then converted into glutamine by glutamine synthetase (GS) and transported back to
the presynaptic neuron (Norenberg and Martinez-Hernandez, 1979). This is referred to as the
glutamate/glutamine cycle (Revett et al., 2013), a critical regulation point for the glutamatergic
system to terminate receptor signaling while preventing excess accumulation of
synaptic glutamate potentially leading to excitoxicity (Olney et al., 1997). As well,
dysregulation of glucose metabolism can potentially impact glutamate synthesis in
the glutamate/glutamine cycle (Knight et al., 2014), underlining the importance of this regulatory
cycle for learning and memory (Valladolid-Acebes et al., 2012; Hascup et al., 2019a).

Alterations in Glutamatergic Signaling Throughout Alzheimer’s Disease
Progression
The Relationship Between Aβ and Glutamate
Alzheimer’s disease (AD) is characterized by excitotoxic levels of extracellular
glutamate alongside accumulation of soluble Aβ and hyperphosphorylated tau
protein leading to neuronal cell death (Hiruma et al., 2003; Kopeikina et al.,
2012). Evidence shows that soluble Aβ accumulation results in synaptic
failure, potentially through modifications to the glutamatergic system (Walsh et al., 2002;
Wang et al.,
2002; Barghorn
et al., 2005; Cleary et al., 2005; Selkoe, 2008; Ferreira and Klein, 2011; Wilcox et al., 2011).
Early stages of the disease show an increased excitability of pyramidal neurons
(Grutzendler et al.,
2007; Šišková
et al., 2014; Hascup and Hascup, 2015) and an upregulation of glutamatergic
presynaptic boutons as observed in mild cognitive impairment (MCI; Bell et al., 2007) and
in mouse models of AD (Hascup et al., 2019a). Several studies have noted hyperactivity in
the hippocampus of MCI patients (Bell et al., 2007; Miller et al., 2008;
O’Brien et al.,
2010; Huijbers
et al., 2015) with familial history of AD (Okonkwo et al., 2014) and elevated Aβ
deposition (Huijbers et al.,
2015) also contributing to excitability. In fact, hyperactivity at
baseline, as detected by functional magnetic resonance imaging, is associated
with increased severity of cognitive decline (Miller et al., 2008; O’Brien et al., 2010;
Huijbers et al.,
2015).

Along with increased excitability, morphological changes in dendritic structure
of hippocampal pyramidal neurons have been noted (Grutzendler et al., 2007; Šišková et al., 2014),
with specific responsiveness to amyloid plaques (Masliah et al., 1993; Ovsepian et al.,
2018). Whole-cell patch clamp recordings of CA1 pyramidal neurons in
AβPP/PS1ΔE9 (APP/PS1; RRID:MMRRC_034832-JAX) mice show reductions in length,
branching, and surface area of dendrites while also displaying a localized
hyperactivity effect and increased synaptic integration that is attributed to
the changes in dendritic structure (Šišková et al., 2014). Similar
morphological changes appear in the PSAPP double transgenic mouse model (Tg2576
RRID:
IMSR_TAC:1349; PSEN1 (M146L): RRID:
IMSR_JAX:033255) and postmortem AD brain samples (Grutzendler et al.,
2007).

Later stages of AD show markedly decreased glutamatergic activity in stark
juxtaposition to earlier hyperactivity. The APP/PS1 AD mouse model shows
increased stimulus-evoked glutamate release at younger ages, which then steadily
decreases with age and Aβ accumulation (Minkeviciene et al., 2008; Hascup and Hascup,
2015; Hascup et al.,
2019b). Busche
et al. (2012) also note increased glutamatergic hyperactivity in
young APPswe/PS1G384A double transgenic mice (APPswe:
RRID: MGI:
3665286; PS1G384A: RRID: MGI:
4819108), with hyperactive neurons preferentially surrounding
amyloid plaques. Such findings are observed in AD patients, with a decrease in
presynaptic glutamatergic boutons and glutamate signaling noted in later disease
stages (Bell et al.,
2007; Miller
et al., 2008; O’Brien et al., 2010). This could result in chronically elevated
glutamate levels eventually leading to inhibition of axonal transport and
neurodegeneration through Aβ accumulation and increased Ca2+
intracellular concentrations (Hiruma et al., 2003; Stutzmann, 2005).

Studies attempting to characterize disease cell signaling and pathology in human
AD typically use postmortem tissue due to logistical difficulties in obtaining
tissues and data from patients in earlier disease stages. Such limitations
hinder study of earlier cell signaling changes, although there are some methods
currently used to examine glutamate in live patients. Of note, studies using
proton magnetic resonance spectroscopy (1H MRS) and glutamate chemical exchange
saturation transfer (GluCEST) show decreased overall glutamate concentration in
APP/PS1 mice and AD patients (Rupsingh et al., 2011; Haris et al., 2013).
The hippocampus was specifically noted as having a large decrease in glutamate
concentration, and as previously discussed, the hippocampus is especially
vulnerable to Aβ accumulation. The CA1 region is particularly susceptible to
disease-related neuronal loss (West et al., 1994; Hof et al., 2003) and
shows decreased stimulus-evoked glutamate with age in APP/PS1 mice (Hascup et al., 2016).
This supports that the decrease in total concentration observed may be a
consequence of neuronal loss resulting from excitotoxicity, as opposed to
decreased glutamate concentration in the hippocampus.

These findings display a flexibility in glutamatergic characterization such that
it is specific to the disease stage. The paradoxical nature of glutamate
signaling in AD petitions for a deeper look into the individual impact on
glutamatergic synaptic components throughout disease progression. Modifications
in expression of synaptic elements could lead to alterations in cell signaling,
allowing for excitotoxic conditions to grow and building the foundation for
cognitive decline.

Neuronal Glutamate Synaptic Component Changes in AD
Individual changes in glutamatergic synaptic components underlie the altered
glutamate release observed throughout disease progression. As mentioned
previously, earlier stages are marked with elevated glutamate release that
eventually increases glutamate concentrations in and around the synapse.
Evidence supports that this starts presynaptically, with Aβ and VGluT1
colocalizing on glutamatergic synaptic boutons and preferentially accumulating
in these terminals (Sokolow
et al., 2012). This coincides with elevated expression of VGluT1 in
mouse models of AD, supporting increased vesicle trafficking of glutamate
(Hascup et al., 2019a). Several studies have also shown a downregulation of
VGluT1 expression in AD
(Kashani et al., 2008; Canas et al., 2014; Rodriguez-Perdigon et al.,
2016), but only VGluT2 downregulation in MCI subjects (Kashani et al., 2008), supporting that
VGluT1 levels are not downregulated until later stages of AD. This expression
pattern matches that of glutamate release such that initially more glutamate is
packaged into vesicles for release, contributing to an increase in extracellular
glutamate levels into a toxic range.

Postsynaptically, the impact of Aβ accumulation on AMPA/NMDA receptors has been
well documented. Bath application of Aβ reduces both the amplitude and frequency
of AMPA postsynaptic currents in CA1 pyramidal neurons (Parameshwaran et al., 2007). Neuronal
cell cultures taken from the cortex and hippocampus of Tg2576 transgenic AD mice
show decreased expression of the GluR1 AMPA subunit as Aβ concentrations
increased (Almedia et al., 2005). A decrease in GluR1 and GluR2/3 expression has
also been observed in postmortem AD entorhinal cortex (Yasuda et al., 1995), although GluR2/3
is expressed presynaptically as well. In the hippocampus, ionotropic glutamate
receptor AMPA subunit-4 expression is downregulated in sporadic AD (Jacob et al., 2007),
along with decreased AMPA binding in the CA1 (Dewar et al., 1991). It is arguable
that the decrease in AMPA binding may be due to decreased GluR1 surface
expression caused by decreased expression of synaptic calcium-calmodulin II
(CaMKII) as seen in APP/PS1 mice (Gu et al., 2009). The decreased release
of stimulus-evoked glutamate mentioned earlier could also account for this
decrease in binding (Hascup
and Hascup, 2015). In cell culture, GluA1 expression is upregulated
in APP knockout corticohippocampal neurons supporting that Aβ directly impacts
expression levels of AMPA subunits (Martinsson et al., 2019).
Interestingly, GluR2 has been shown to be upregulated in incipient AD patients
(Williams et al., 2009), supporting that AMPA expression may follow the same
cycle of early upregulation and then subsequent downregulation with AD
progression. Early upregulation is likely a response to increased presynaptic
glutamate stimulation, but overtime, chronic excessive stimulation leads to
desensitization and internalization of the AMPA receptor (Esposito et al., 2013).

NMDA receptors are a cornerstone in the relationship between Aβ accumulation and
glutamate toxicity. Aβ42 preferentially binds to glutamatergic
neurons expressing NR1 or NR2B NMDA subunits compared with other subunits (Lacor et al., 2007).
Aβ42 can stimulate glutamate release, potentially through α7
nicotinic acetylcholine receptors (α7nAChR; discussed later), to activate
E-NMDARs (Talantova et al.,
2013). This can result in long-term potentiation (LTP) inhibition
(Li et al.,
2011; Kervern et al.,
2012) and contribute to synaptic spine loss (Talantova et al., 2013). This
Aβ-mediated increase in glutamate concentration leads to endocytosis and
decreased surface expression of NR1 and NR2B (Snyder et al., 2005). Downregulated
NMDA subunit expression in the hippocampus has been observed in several
postmortem studies in human AD subjects (Hynd et al., 2004a,
2004b; Jacob
et al., 2007).

NMDARs are believed to mediate soluble Aβ-induced cell death such that persistent
activation of NMDA from excessive glutamate release leads to selective neuronal
death from chronic excitotoxicity (Butterfield and Pocernich, 2003).
E-NMDARs allow for Ca2+ entry into the cell (Zhang et al., 2016), which causes
increased dendritic calcium-induced calcium release from ryanodine receptors,
thus increasing intracellular Ca2+ concentrations (Goussakov et al.,
2010). In fact, MCI patients show increased expression of ryanodine
receptor 2 (Bruno et al.,
2012), which would allow for further NMDA-mediated increases in
intracellular Ca2+ concentrations. Overtime, this can eventually
result in toxic Ca2+ levels leading to depolarization of the
mitochondrial membrane, free radical production, and cell death. (Hardingham et al.,
2002; Hardingham and
Bading, 2003; Bezprozvanny and Mattson, 2008; Zhang et al., 2016). Along with this,
E-NMDAR-mediated Ca2+ influx activates cAMP-regulatory element
binding protein (CREB) shut off pathways (Hardingham et al., 2002). CREB plays a
central role in long-term memory (Yin and Tully, 1996; Barco et al., 2003;
Tully et al.,
2003), and downregulation results in memory impairment (Xiong et al., 2013;
Zhang et al.,
2014). Thus, increased intracellular Ca2+ levels resulting
from E-NMDAR stimulation contributes to both cognitive decline and neuronal loss
in AD pathology.

Furthermore, soluble Aβ acts through NMDAR to activate nicotinamide adenine
dinucleotide phosphate oxidase leading to induction of reactive oxygen species
(ROS; Kishida and Klann,
2006) and release of arachidonic acid (Shelat et al., 2008). The influx of
Ca2+ from NMDAR activation is required for ROS formation (De Felice et al.,
2007). Although NMDA production of ROS is a necessary element for LTP
(Kishida and Klann,
2006), Aβ stimulates an excessive ROS induction from NMDARs, leading
to oxidative damage and synaptic failure (De Felice et al., 2007; Shelat et al., 2008).
In fact, elevated ROS levels contribute to impairment of LTP (Serrano and Klann,
2004) and spatial learning (Nicolle et al., 2001) with age. NMDA
activation also increases nitric oxide (NO) synthesis (Garthwaite et al., 1989) in a
Ca2+ (Law
et al., 2001) and postsynaptic density-95 dependent manner (Sattler et al., 1999).
The 3xTg-AD (RRID:
MMRRC_034830-JAX) mouse model shows significant increases in
NMDA-mediated NO concentration peaks in the CA1 at earlier disease stages, which
then substantially decreased with age (Dias et al., 2016), an effect that
could underlie the changes in glutamate cell signaling seen throughout disease
progression. Furthermore, inducible nitric oxide synthase (iNOS) mediates
Aβ-induced LTP inhibition (Wang et al., 2004), while soluble Aβ works through
both NMDA and NOS to increase oxidative stress (Parks et al., 2001). However, NO can
in turn inhibit NMDAR action (Manzoni et al., 1992), which could
play a role in decreased NMDAR activity in later stages of AD. Even with
increasing neurotoxicity, NOS+ neurons in the hippocampus are relatively spared
(Hyman et al.,
1992), supporting a complicated relationship between NO and glutamate
such that NO provides some neuroprotection while also contributing to the
consequences of excitotoxicity.

Studies performed in primary cortical neuron cultures have shown seemingly
opposing results on NMDA modulation of APP processing. NMDA (50 µM) treatment
showed both induction of Kunitz protease inhibitory domain (KPI)-APP neuronal
expression promoting production of Aβ42 (Lesné et al., 2005), and increases in
α-carboxyterminal fragment levels, supporting enhancement of nonamyloidogenic
α-secretase cleavage (Hoey
et al., 2009). Interestingly, the increase in α-carboxyterminal
fragment levels was not observed in isolated E-NMDARs, supporting that this is
solely an S-NMDAR effect (Hoey et al., 2009). Furthermore, Lesné et al. (2005) used a longer NMDA
incubation period (24 hr) to create an excitotoxic environment, as would be
observed with chronic E-NMDAR stimulation. Bordji et al. (2010) addressed these
conflicting findings by isolating either S-NMDARs or E-NMDARs in primary
cortical neuron culture. While S-NMDARs were shown to have no impact on KPI-APP
neuronal expression, E-NMDARs increased KPI-APP expression at the 12- and 24-hr
time points. This E-NMDAR-mediated increase in KPI-APP expression was also found
to be calcium-calmodulin dependent, supporting induction through NMDA-mediated
Ca2+ entry into the neuron. Along with these findings, NMDA
antagonists are capable of blocking Aβ42 uptake into hippocampal
neurons (Bi et al., 2002) where Aβ can reduce axonal transport through an
NMDA/glycogen synthase kinase-3β dependent mechanism (Decker et al., 2010). This further
emphasizes the critical roles of E-NMDARs in AD, impacting both APP processing
and Aβ42 internalization, and thereby establishing E-NMDARs as a
central mediator to the neurotoxic effects of Aβ.

Autoradiography studies of postmortem brain tissue shows decreased binding to
mGluRs and decreased mGluR/neuronal density ratio (Dewar et al., 1991; Albasanz et al., 2005).
This effect was associated with a decrease in mGluR1 expression, which
continuously declines with AD progression (Albasanz et al., 2005). Interestingly,
another study found mGluR2, which is primarily expressed presynaptically, to be
upregulated in AD (Lee
et al., 2004). mGluR2 protects against excitotoxicity by inhibiting
presynaptic glutamate release (Buisson and Choi, 1995; Imre, 2007; Hascup et al., 2010;
Quintero et al.,
2011; Hascup
et al., 2019b) and has been shown to directly activate extracellular
signal-regulated kinase (ERK) in a phosphoinositide 3-kinase (P13K)-dependent
manner (Ferraguti et al.,
1999). ERK impacts CREB phosphorylation and promotes cell survival
(Lu and Xu,
2006; Lee et al.,
2009) but also phosphorylates tau which can contribute to aberrant
hyperphosphorylation resulting in neurofibrillary tangles (Lee et al., 2009). These findings
support that while this mechanism may initially be neuroprotective (Bond et al., 2000),
over time, it may contribute to disease pathology.

Astrocytic Glutamate Component Changes in AD
Astrocytes play a key role both in the tripartite glutamatergic synapse and in AD
pathogenesis (Rudy et al.,
2015). Reactive astrocytes are known to associate with senile plaques
in AD mouse models and human tissue (Verkhratsky et al., 2010; Rodríguez-Arellano et al.,
2016), leading to astrogliosis in the hippocampus and cortex
characterized by increased expression of glial fibrillary acidic protein (GFAP;
Nagele et al.,
2004; Olabarria
et al., 2010; Hascup et al., 2019a). This response is triggered by damaged
neuronal signals, referred to as damaged-associated molecular patterns, and Aβ
plaque deposition (Verkhratsky et al., 2010) leading to increased release of
proinflammatory factors such as interleukin-1β (IL-1β) and tumor necrosis
factor-α (Morales et al.,
2014). Continuing induction of astrocytic response leads to chronic
inflammation that results in cell damage (Streit et al., 2004).

Glutamate clearance from the synapse is hindered in AD through decreased uptake
into astrocytes. This is supported by decreased expression of both GLT-1 and
GLAST in the hippocampus (Cassano et al., 2012) that appears prior to plaque deposition (Schallier et al.,
2011). In later stages, GLT-1 expression is markedly decreased around
plaques (Hefendehl et al.,
2016). Expression of GLT-1 may be directly impacted by Aβ through
lipid peroxidation and 4-hydroxynonenal modification as a result of oxidative
stress (Butterfield et al.,
2002). This change in GLT-1 expression contributed to spatial
learning deficits in earlier stages (6 months old) but did not cause a
significant deviation in cognitive performance in 9-month-old APP/PS1 mice
lacking one GLT-1 allele (Mookherjee et al., 2011). This effect is also observed with
decreased expression of EAAT-2 (the human GLT-1 equivalent) in postmortem AD
cortex (Scott et al.,
2011) as well as EAAT-1 (GLAST) reduction in the hippocampus (Jacob et al., 2007).
Again, this reduction was specifically noted in the vicinity of senile plaques
(Jacob et al.,
2007; Hefendehl
et al., 2016), supporting elevated basal glutamate surrounding
plaques in both mouse and human models. Interestingly, several disease-specific
splice variants of EAAT2 exist that reduce the glutamate transport capacity of
EAAT2 in AD postmortem tissue (Scott et al., 2011). This may offer an
additional avenue for excitoxicity, whereby glutamate transporters are both
downregulated and have decreased functional glutamate clearance.

GS action upon glutamate is a critical component in preventing excitotoxicity
(Verkhratsky and
Kirchhoff, 2007; Rudy et al., 2015) but shows altered expression in AD (Robinson, 2001; Boyd-Kimball et al.,
2005; Olabarria
et al., 2011; Palmieri et al., 2017; Huang et al., 2016). In 3xTg-AD mice, GS+
astrocyte distribution mirrored that of GFAP+ distribution in the DG and CA1,
but by 12 months of age, GS+ astrocyte cell counts decreased, and by 18 months
of age, downregulation of GS expression in the hippocampus was observed (Olabarria et al.,
2011). Human tissue taken from patients with advanced AD also shows a
decrease in GS expression. Interestingly, less GS staining was observed
clustering around plaques, unlike GFAP+ astrocytes (Robinson, 2001). This is possibly due
to the level of neuronal loss experienced during advanced stages of AD (DeKosky and Scheff,
1990; Selkoe,
2002). GS is particularly vulnerable to oxidative modification (Boyd-Kimball et al.,
2005) that makes it a potential target of Aβ-induced oxidative damage
(Huang et al., 2016). Along with this, GS inhibition in activated microglia
results in stronger induction of inflammatory markers which increases neuronal
toxicity (Palmieri et al.,
2017).

The evidence presented for both neuronal and astrocytic components of the
tripartite glutamate synapse involvement in AD progression support that Aβ can
impact the glutamatergic system through various mechanisms. Changes in
expression of each of the synaptic components lead to chronically elevated
extracellular glutamate that becomes excitotoxic and underlies AD pathology.

Aβ–α7nAChR Interactions
α7nAChRs are expressed on both neurons and glia, with hippocampal immunostaining
showing the highest density of α7nAChR-expressing neurons in the neuropil and
α7nAChR-expressing glia in the distal regions of the stratum radiatum (Gahring et al., 2004). It
has been well established in the literature that application of nicotine elicits
glutamate release both in vitro and in vivo (Marchi et al., 2002; Lambe et al., 2003; Konradsson-Geuken et al.,
2009). In vivo microelectrode array recording studies
have shown nicotine-induced glutamate release in the prefrontal cortex of freely
moving rats, that is attenuated with application of α-bungarotoxin, an α7nAChR
antagonist (Konradsson-Geuken
et al., 2009). Soluble Aβ40 and Aβ42 interact with
nAChRs at these synapses (Wang et al., 2000a,
2000b) impacting glutamate release. Aβ interacts with both α7 and α4β2
nAChRs; however, α4β2nAChR receptor binding requires a significantly higher
concentration than α7nAChR (Wang et al., 2000b). Regarding differences between Aβ40 and
Aβ42, Aβ40 was found to bind with less affinity and
decreased potency compared with Aβ42 (Wang et al., 2000a; Dineley et al., 2002a). More specifically,
Aβ42 binds with femtomolar affinity to the nicotine/acetylcholine
(ACh)-binding pocket of α7nAChR (Wang et al., 2000b; Magdesian et al., 2005) and can elicit
different responses dependent on Aβ preparation and concentration used (Parri et al., 2011; Hascup and Hascup, 2016).
High concentrations of Aβ (nM-µM) noncompetitively block hippocampal α7nAChRs in
in vitro hippocampal cell culture and slices (Liu et al., 2001; Mura et al., 2012).
Alternatively, low concentrations of Aβ (fM-pM) have been shown to potentiate
glutamate release (Puzzo
et al., 2008; Mura
et al., 2012; Hascup
and Hascup, 2016) with some effects on aspartate and GABA release also
observed in vivo (Mura et al., 2012). In fact, Aβ-stimulated
α7nAChR glutamate release from neurons and astrocytes can result in rising
extracellular glutamate levels that can chronically activate E-NMDARs, thereby
contributing to excitotoxicity (Rudy et al., 2015).

Lower concentrations of Aβ42 have been shown to enhance LTP and spatial
memory performance in C57BL/6 mice (RRID:
IMSR_JAX:000664; Puzzo et al., 2008), while higher concentrations result in LTP deficits
(Chen et al., 2006, 2010; Gu and Yakel, 2011). The LTP-enhancing
aspect of Aβ42 is not mediated by AMPA/NMDA receptors, as Aβ42
perfusion of hippocampal slices does not impact AMPA/NMDA receptor currents or
amplitude frequency and distribution (Puzzo et al., 2008). This
concentration-dependent action of Aβ supports a transformation from excitation to
inhibition of α7nAChRs as AD progresses, with Aβ levels rising from picomolar to
nanomolar levels (Näslund
et al., 1994; Auld
et al., 1998; Puzzo and Arancio, 2012). It should be noted that
presynaptic α7nAChRs are known to interact with neighboring NMDARs such that the
chronic inactivation of α7nAChR, resulting from desensitization by Aβ, could result
in enhanced NMDAR function (Lin
et al., 2010). However, this increased presynaptic glutamate release may
not evoke LTP enhancement as postsynaptic AMPA/NMDA receptors become desensitized
and downregulated in the excitotoxic state associated with AD (Yasuda et al., 1995; Selkoe, 2002; Hynd et al., 2004a,
2004b; Parameshwaran
et al., 2007).

Evidence of Aβ42 concentration-dependent α7nAChR modulation is further
characterized through microelectrode array recordings in the hippocampus. Hascup and Hascup (2016)
showed glutamatergic stimulation with local application of Aβ42 in
hippocampal recordings from anesthetized C57BL/6 mice, an effect that was blocked
with co-application of α-bungarotoxin supporting involvement of α7nAChR.
Interestingly, different responses to Aβ42 application were observed
depending on the hippocampal subfield, with the CA1 and dentate gyrus responding
most to lower concentrations of Aβ42 compared with the CA3. These
findings mirror current knowledge of AD disease progression, with the CA1 showing
the earliest increases in glutamate release in the APP/PS1 transgenic AD mouse model
(Hascup and Hascup,
2015) and the earliest site of plaque deposition for the hippocampus in
human AD patients (Thal et al.,
2000; Shie et al.,
2003).

α7nAChRs open upon nicotine binding, allowing a Ca2+ influx into the
presynaptic neuron (Gray et al.,
1996). Similarly, binding of soluble Aβ to the α7nAChR triggers an influx
of Ca2+ into the presynaptic neuron (Dineley et al., 2001,
2002a; Dougherty
et al., 2003) and has been shown to activate the ERK/mitogen-activated
protein kinases pathway (Dineley
et al., 2001; Bell
et al., 2004; Abbott
et al., 2008; Young
et al., 2009) in a P13K-dependent manner (Bell et al., 2004) which in turn impacts
the phosphorylation of CREB (Dineley et al., 2001). Intraperitoneal injection of α7nAChR selective
agonist A-582941 resulted in increased ERK 1/2 and CREB phosphorylation that
improved behavioral performance on delayed matching to sample titration, inhibitory
avoidance, and social recognition (Bitner et al., 2007). However, in the
Tg2576 mouse model, CREB was found to be upregulated at 13 months of age and then
downregulated by 20 months of age (Dineley et al., 2001). This supports that
CREB activation mirrors the Aβ-α7nAChR interaction such that CREB expression is
enhanced in the early stages of AD when there are lower concentrations of Aβ, and
then decreases with disease progression corresponding to Aβ accumulation.

The potentiation of glutamate release from Aβ activation of α7nAChR contributes to
excitotoxicity while also resulting in rapid desensitization of the α7nAChR (Dineley et al., 2002b).
Aβ42 and α7nAChR have been shown to form a complex that becomes
internalized in the neuron and leads to cell lysis and plaque deposition (D’Andrea et al., 2001;
Nagele et al., 2002;
Deutsch et al., 2014;
Godyń et al., 2016).
In fact, Aβ accumulates at a faster rate in neuroblastoma cells transfected with
α7nAChR (Nagele et al., 2002). The Aβ42-α7nAChR complex internalization
leads to decreased surface expression of α7nAChR (Nagele et al., 2002), coinciding
with upregulation of α7nAChR seen throughout AD progression (Hellström-Lindahl et al., 1999; Dineley
et al., 2001, 2002b; D’Andrea and Nagele, 2006) supporting an α7nAChR compensatory mechanism
for decreased surface expression. Interestingly, this chronic desensitization of
α7nAChR has been shown to increase NMDAR surface expression (Lin et al., 2010), suggesting a complex
compensatory response to accumulation of Aβ42.

Learning and Memory Consequences of Altered Glutamatergic Signaling
Glutamatergic dysfunction due to deregulation of synaptic components has phenotypic
consequences in the form of decreased learning and memory performance.
Presynaptically, reductions in VGluT1 and VGluT2 correlated with decline in
cognitive status and disease duration in AD patients (Kashani et al., 2008). Cognitive ability is
negatively correlated with glutamate presynaptic bouton density in MCI patients such
that the increase in bouton density leads to decreased cognitive ability (Bell et al., 2007).
Similarly, elevated hippocampal glutamate release negatively correlated with
cognitive performance prior to cognitive decline in APP/PS1 mice (Hascup and Hascup, 2015).
This is in stark contrast to cognitively normal patients that have a positive
correlation (Bell et al.,
2007), supporting a threshold in which increased glutamate signaling
switches from stimulating to hindering cognition.

NMDA and mGluRs are both known to play vital roles in induction of LTP and long-term
depression (LTD; Parameshwaran et al., 2007; Shankar et al., 2008). Soluble Aβ inhibits
S-NMDARs that are required for LTP conduction (Collingridge and Bliss, 1995; Parsons et al., 2007).
Treatment with (2R)-amino-5-phosphonovaleric acid (D-AP5), a
selective NMDA antagonist, impairs LTP in vivo supporting that the
involvement of NMDARs in LTP (Davis et al., 1992). However, in GLT-1 knockout mice, the LTP impairment
observed was reversed with application of D-AP5, supporting that both blockade and
overactivation of NMDARs can interfere with LTP (Katagiri et al., 2001). This effect may be
due to the involvement of E-NMDARs, whereby inhibition of E-NMDARs prevents
Aβ-mediated LTP impairments (Li
et al., 2011; Rammes
et al., 2011). Memantine, an FDA-approved noncompetitive NR2 antagonist
(Parsons et al.,
1998) for treating AD has shown efficacy in improving Morris water maze
performance (Barnes et al.,
1996; Van Dam
et al., 2005; Banerjee
et al., 2006) and blocked Aβ inhibition of LTP in 3xTg-AD hippocampal
slices (Parsons et al.,
2009; Martinez-Coria
et al., 2010). Thus, supporting that noncompetitive inhibition of NR2+
NMDARs provides a counterbalance to both inhibition of S-NMDARS and overactivation
of E-NMDARS, explored further in the next section.mGluRs are involved in both the
Aβ-induced suppression of LTP and potentiation of LTD (Wang et al., 2004; Shankar et al., 2008;
Rammes et al.,
2011). Aβ-mediated LTP impairments can be blocked by inhibition of mGluR5
(Wang et al., 2004; Rammes
et al., 2011). As NMDARs and mGluRs are mechanistically coupled, chronic
stimulation of either can lead to synaptic failure as seen in AD (Rammes et al., 2011; Kervern et al., 2012). This
failure is potentially due to Ca2+ dysregulation and dephosphorylation of
CREB as both E-NMDARs and mGluR5 elevate intracellular Ca2+ (Chen et al., 2002; Hardingham et al., 2002;
Hardingham and Bading,
2003; Verkhratsky
and Kirchhoff, 2007; Yamin, 2009; Zhang
et al., 2016). In addition, mGluR1 has been shown to be involved in
synaptic plasticity and LTP in the CA1 (Neyman and Manahan-Vaughan, 2008; Rudy et al., 2015). Of
note, agonism of mGluR1 and mGluR5 with 3-hydroxyphenylglycine potentiated
NMDAR-induced neurotoxicity, juxtaposing the neuroprotective effects observed with
mGluR2 agonism (Buisson and
Choi, 1995; Tyszkiewicz and Yan, 2005) and further supporting a
deleterious relationship between NMDAR and mGluRs upon LTP and excitotoxicity.
Furthermore, mGluRs are required for soluble Aβ-mediated LTD enhancement (Shankar et al., 2008;
Palop and Mucke,
2010; Um et al.,
2013). Treatment with a similar Group I mGluR agonist,
3,5-dihydroxyphenylglycine, results in decreased AMPAR surface expression during LTD
(Um et al., 2013),
supporting another mechanism by which soluble Aβ impacts learning and memory signal
conductance.

Theories on the Paradoxical Nature of Glutamate in AD
The two-stage model theory was first set forth by Olney et al. (1997) describing two stages
of NMDAR-mediated toxicity in AD pathology. The first stage, referred to as NRHyper,
describes persistent activation of NMDA receptors. Chronic NMDAR stimulation then
leads to the second disease stage, referred to as NRHypo, in which the NMDARs become
hypoactive as a result of chronic overstimulation leading to inhibition of LTP
conductance and cognitive decline. These disease stages are driven by soluble Aβ
accumulation. During the NRHyper phase, Aβ potentiates glutamate release and
increases NMDA activation and sensitivity to glutamate. This leads to partial
membrane depolarization allowing tonic activation of NMDA receptors (Koh et al., 1990; Gray and Patel, 1995; Danysz and Parsons, 2012).
This overstimulation subsequently results in an NRHypo state in which glutamatergic
activation is depressed and synaptic components are downregulated. NMDARs become
hypofunctional in normal brain aging; however, this is experienced to an extreme in
AD possibly due to the increase hyperactivation state experienced in AD that
precedes hypoactivation. NMDAR hypoactivation applies to NMDARs on GABAergic neurons
as well, causing disinhibition of the glutamatergic system and resulting in
increased extracellular glutamate concentrations and neuronal loss. This is expanded
upon by the findings of Huijber et al. (2015) and the trait versus state hypothesis
set forth by Aizenstein and Klunk
(2015), describing two models of hippocampal activity such that some
individuals have a trait of high levels of hippocampal activation
prior to MCI and some experience hyperactivation as a state with
MCI onset. Both models subsequently result in cognitive decline and support a period
of hippocampal hyperactivation occurring before hypoactivation.

Similarly, Parsons et al.
(2007) proposed the signal-to-noise ratio hypothesis. This hypothesis
notes that in AD pathology, NMDAR is stimulated by glutamate for longer periods of
time due to a hyperactive glutamatergic system (Buisson et al., 1992; Mitani et al., 1992). As such, this leads
to tonic activation of NMDAR that generates increasing amounts of
noise. This noise raises the threshold by which neuronal
stimulation must pass to generate a stimulus-evoked signal. With
disease progression, the increased noise eventually drowns out the signal, leading
to learning and memory deficits seen in AD. This effect has been observed in our
lab, with APP/PS1 mice showing a decline in stimulus-evoked glutamate and an
increase in basal glutamate levels with disease progression, impacting spatial
memory performance (Hascup and
Hascup, 2015). This hypothesis is further elucidated with the proposed
action of memantine, the noncompetitive NR2 antagonist, which shows fast unblocking
kinetics dependent upon membrane potential. This characteristic allows memantine to
quickly unblock the NMDAR during strong depolarization of the postsynaptic membrane
and remain bound during tonic stimulation. In fact, recovery from memantine blockade
is shown to be even faster in the presence of higher synaptic glutamate
concentrations (Clements et al.,
1992). Memantine benefits both S-NMDARs and E-NMDARs in LTP such that LTP
conductance is not hindered at the synapse but chronic stimulation of E-NMDARs is
blocked, ultimately helping to alleviate excitotoxic effects. This is seen with
memantine improvements in LTP induction and Morris water maze performance as
discussed earlier (Barnes
et al., 1996; Van
Dam et al., 2005; Banerjee et al., 2006; Parsons et al., 2009; Martinez-Coria et al.,
2010). Of note, memantine has also showed efficacy in reducing Aβ
production brought on by E-NMDAR prolonged activation (Bordji et al., 2010), as well as reducing
the levels of both soluble Aβ and insoluble Aβ plaques in 3xTg-AD mice (Martinez-Coria et al.,
2010) and blocking soluble Aβ-induced oxidative stress (De Felice et al., 2007). As
such, memantine shows modulation of Aβ-and-glutamate-induced neurotoxicity giving
support to the idea that noise created by extracellular glutamate overpowers
stimulus-evoked glutamate signals in AD.

In clinical trials, memantine was shown to reduce cognitive deficits in mild to
severe AD patients (Winblad and
Poritis, 1999; Reisberg et al., 2003; Peskind et al., 2006). A meta-analysis of
memantine trials also revealed efficacy in treating patients with moderate to severe
AD (Winblad et al.,
2007). However, the weak procognitive effects observed in AD patients treated
with memantine (McShane et al.,
2006; Schneider
et al., 2011) may be due to the disease stage when treatment was
initiated. If memantine treatment is initiated too late in disease progression,
neuronal loss may be too severe to yield procognitive effects. As such, post hoc
analysis of nine clinical trials of memantine show delay of clinical worsening in
moderate to severe AD patients (Hellweg et al., 2012). Danysz and Parsons (2012) argue that starting
treatment in the prodromal stage of AD would allow for memantine-induced
neuroprotection, which could yield more promising clinical results and further delay
cognitive decline.

In addition, NMDARs are not the only components that modulate the signal-to-noise
ratio. mGluRs are multifaceted due to their G-protein and NMDAR coupling and as such
are also a vital mediator in LTP. Riedel (1996) has argued that mGluRs are
responsible for the initial setup of the signal-to-noise ratio to allow for
efficient plasticity. Pretraining injection of mGluR agonists leads to nonspecific
activation of Group I mGluRs, generating an increase in noise and preventing memory
formation. Groups II and III mGluRs then act as mediators to reduce noise and allow
for signal conductance and memory formation. This initial organization of the
signal-to-noise ratio is impacted at the mGluR level in AD pathology, as mentioned
earlier with mGluR1 and mGluR5 potentiating NMDA-induced neurotoxicity and then
experiencing a downregulation in expression in later disease stages (Buisson and Choi, 1995;
Albasanz et al.,
2005), following a similar hyper- to hypoactivation trend. This initial noise
generation overpowers the inhibitory modulation of mGluR2, despite its upregulation
in early AD (Buisson and Choi,
1995). However, our laboratory recently demonstrated that prodromal
treatment with the mGluR Group II agonist LY379268 does not offer long-term
procognitive benefits in APP/PS1 mice (Hascup et al., 2019b).

Furthermore, our laboratory and others have reported a relationship between Aβ and
glutamate mediated by α7nAChR stimulation that contributes to increases in glutamate
release (Puzzo et al.,
2008; Mura et al.,
2012; Hascup and
Hascup, 2016), generating a large amount of signal. This relationship
changes as AD progresses and Aβ increases in concentration and plaque formation such
that we see an opposite impact through α7nAChR in which glutamate release is
inhibited and thus contributes to overall hypoactivation (Liu et al., 2001; Mura et al., 2012). Interestingly, α7nAChR
desensitization leads to increased NMDAR surface expression and enhanced function
(Lin et al., 2010),
and both pathways modulate Aβ toxicity such that α7nAChR and E-NMDARs lead to
Aβ42 internalization (D’Andrea et al., 2001; Bi et al., 2002;
Nagele et al., 2002;
Deutsch et al., 2014;
Godyń et al., 2016),
and E-NMDARs lead to increased amyloidogenic processing (Bordji et al., 2010). In addition,
nicotine-mediated enhancement of LTP is both NMDA and mGluR5 dependent (Welsby et al., 2006), and
because Aβ42 binds to the same pocket as nicotine, it follows that mGluR5
may potentiate both NMDA and α7nAChR-induced excitotoxicity. Other pathways
previously discussed in this review also result in toxic Ca2+
intracellular levels and modulation in CREB expression that result in neuronal cell
loss. This interaction between multiple glutamatergic pathways emphasizes the
breadth of Aβ modulation of the glutamatergic system to generate neurotoxicity as
outlined in Figure 1.

Figure 1. Changes in glutamatergic synapse component expression and signaling with AD
progression. (a) Preclinical AD upregulation of several neuronal components
contributing to hyperactivation and building the foundation for
excitotoxicity. (b) Clinical AD is characterized by hypoactivation of the
glutamatergic system, possibly a consequence of the earlier preclinical
stage. This results in cognitive deficits due to signal-to-noise ratio
imbalance.

AD = Alzheimer’s disease; α7nAChR = alpha-7 nicotinic acetylcholine receptor;
Aβo = amyloid beta oligomer; VGluT1 = vesicular glutamate
transporter 1; AMPAR = α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
receptor; E-NMDAR = extrasynaptic
N-methyl-D-aspartic acid receptor;
mGluR = metabotropic glutamate receptor; S-NMDAR = synaptic
N-methyl-D-aspartic acid receptor;
EAAT = excitatory amino acid transporter.

Conclusion
Taken together, the presented evidence supports a signal-to-noise ratio imbalance
occurring in AD pathology. Aβ modulates several parts of the tripartite
glutamatergic synapse that culminates in an excitotoxic environment. The excitation
threshold at which glutamate signals must surpass for learning and memory increases
while also undergoing an overall dampening of the glutamatergic system. Loss of
signal detection due to persistently elevated synaptic and extrasynaptic glutamate
levels leads to the hallmark symptoms of cognitive deficits and eventual neuronal
loss in AD disease progression.

Summary
Glutamatergic transmission displays stark changes throughout AD progression. Earlier
stages are characterized by upregulation of synaptic components contributing to
increased glutamate signaling. Later stages exhibit hypoactivation possibly due to
cell damage and neuronal loss, subsequently resulting in cognitive decline.

Author Contributions
All authors were involved with the article preparation and editing.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the
research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research,
authorship, and/or publication of this article: Research reported in this
publication was supported by the National Institute on Aging of the National
Institutes of Health under Award Number R01AG057767 and R01AG061937, the Illinois
Department of Public Health under Award Numbers 63282003D and 83282002F, the Center
for Alzheimer’s Disease and Related Disorders at Southern Illinois University School
of Medicine, the Kenneth Stark Endowment, the Fraternal Order of Eagles, and the
American Diabetes Association under Award Number 1-19-IBS-126 and does not
necessarily represent the official views of the funding agencies.
==== Refs
References
Abbott J. J. Howlett D. R. Francis P. T. Williams R. J.   (2008 ). Aβ1-42 modulation of Akt
phosphorylation via α7 nAChR and NMDA receptors .
Neurobiol Aging , 29 (7 ),
992 –1001 .
doi:10.1016/j.neurobiolaging.2007.01.00317292512 
Aizenstein H. J. Klunk W. E.   (2015 ). Where is hippocampal
activity in the cascade of Alzheimer’s disease biomarkers? 
Brain , 138 (4 ),
831 –833 .
doi:10.1093/brain/awv00125802317 
Albasanz J. L. Dalfó E. Ferrer I. Martín M.   (2005 ). Impaired metabotropic
glutamate receptor/phospholipase C signaling pathway in the cerebral cortex
in Alzheimer’s disease and dementia with Lewy bodies correlates with stage
of Alzheimer’s-disease-related changes. 
Neurobiol Dis , 20 (3 ),
685 –693 .
doi:10.1016/j.nbd.2005.05.00115949941 
Almeida, C. G., Tampellini, D.,
Takahashi, R. H., Greengard, P., Lin, M. T., Snyder, E. M., Gouras, G. K.
(2005). Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1
in synapses. Neurobiol Dis, 20(2), 187–198.
doi:10.1016/j.nbd.2005.02.008
Ambrosini A. Bresciani L. Fracchia S. Brunello N. Racagni G.   (1995 ). Metabotropic glutamate
receptors negatively coupled to adenylate cyclase inhibit
N-methyl-D-aspartate receptor activity and prevent neurotoxicity in
mesencephalic neurons in vitro. 
Mol Pharmacol , 47 (5 ),
1057 –1064 . Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/77462737746273 
Antal M. Fukazawa Y. Eördögh M. Muszil D. Molnár E. Itakura M. Takahashi M. Shigemoto R.   (2008 ). Numbers, densities, and
colocalization of AMPA- and NMDA-type glutamate receptors at individual
synapses in the superficial spinal dorsal horn of rats. 
J Neurosci , 28 (39 ),
9692 –9701 .
doi:10.1523/JNEUROSCI.1551-08.200818815255 
Auld D. S. Kar S. Quirion R.   (1998 ). β-Amyloid peptides as direct
cholinergic neuromodulators: A missing link? 
Trends Neurosci , 21 (1 ),
43 –49 .
doi:10.1016/S0166-2236(97)01144-29464686 
Banerjee P. K. Billings Luhrs L. LeFerla F. M.   (2006 ). P1-001. 
Alzheimers Dement , 2 (3 ),
S94 . doi:10.1016/j.jalz.2006.05.376
Barco A. Pittenger C. Kandel E. R.   (2003 ). CREB, memory enhancement and
the treatment of memory disorders: Promises, pitfalls and
prospects. 
Expert Opin Ther Targets , 7 (1 ),
101 –114 .
doi:10.1517/14728222.7.1.10112556206 
Barghorn S. Nimmrich V. Striebinger A. Krantz C. Keller P. Janson B. Bahr M. Schmidt M. Bitner R. S. Harlan J. Barlow E. Ebert U. Hillen H.   (2005 ). Globular amyloid
beta-peptide1-42 oligomer – A homogenous and stable neuropathological
protein in Alzheimer’s disease. 
J Neurochem , 95 (3 ),
834 –847 .
doi:10.1111/j.1471-4159.2005.03407.x16135089 
Barnes C. A. Danysz W. Parsons C. G.   (1996 ). Effects of the uncompetitive
NMDA receptor antagonist memantine on hippocampal long-term potentiation,
short-term exploratory modulation and spatial memory in awake, freely moving
rats. 
Eur J Neurosci , 8 (3 ),
565 –571 . Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/89634488963448 
Bell K. A. O’Riordan K. J. Sweatt J. D. Dineley K. T.   (2004 ). MAPK recruitment by
beta-amyloid in organotypic hippocampal slice cultures depends on physical
state and exposure time. 
J Neurochem , 91 (2 ),
349 –361 .
doi:10.1111/j.1471-4159.2004.02722.x15447668 
Bell K. F. S. Bennett D. A. Cuello A. C.   (2007 ). Paradoxical upregulation of
glutamatergic presynaptic boutons during mild cognitive
impairment. 
J Neurosci , 27 (40 ),
10810 –10817 .
doi:10.1523/JNEUROSCI.3269-07.200717913914 
Bezprozvanny I. Mattson M. P.   (2008 ). Neuronal calcium mishandling
and the pathogenesis of Alzheimer’s disease. 
Trends Neurosci , 31 (9 ),
454 –463 .
doi:10.1016/J.TINS.2008.06.00518675468 
Bi, X., Gall, C. M., Zhou, J., Lynch, G.
(2002). Uptake and Pathogenic Effects of Amyloid Beta 1-42 Are Enhanced by
Integrin Antagonists and Blocked by NMDA Receptor Antagonists.
Neuroscience, 112(4), 827–840. Retrieved from:
https://www.ncbi.nlm.nih.gov/pubmed/12088742
Bitner R. S. et al  (2007 ). Broad-spectrum efficacy
across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism
correlates with activation of ERK1/2 and CREB phosphorylation
pathways. 
J Neurosci , 27 (39 ),
10578 –10587 .
doi:10.1523/JNEUROSCI.2444-07.200717898229 
Bond A. Jones N. M. Hicks C. A. Whiffin G. M. Ward M. A. O’Neill M. F. Kingston A. E. Monn J. A. Ornstein P. L. Schoepp D. D. Lodge D. O’Neill M. J.   (2000 ). Neuroprotective effects of
LY379268, a selective mGlu2/3 receptor agonist: Investigations into possible
mechanism of action in vivo . J Pharmacol Exp
Ther , 294 (3 ),
800 –809 .10945827 
Bordji K. Becerril-Ortega J. Nicole O. Buisson A.   (2010 ). Activation of extrasynaptic,
but not synaptic, NMDA receptors modifies amyloid precursor protein
expression pattern and increases amyloid-ß production. 
J Neurosci , 30 (47 ),
15927 –15942 .
doi:10.1523/JNEUROSCI.3021-10.201021106831 
Boyd-Kimball D. Sultana R. Fai Poon H. Lynn B. C. Casamenti F. Pepeu G. Klein J. B. Butterfield D. A.   (2005 ). Proteomic identification of
proteins specifically oxidized by intracerebral injection of amyloid
β-peptide (1–42) into rat brain: Implications for Alzheimer’s
disease. 
Neuroscience , 132 (2 ),
313 –324 .
doi:10.1016/j.neuroscience.2004.12.02215802185 
Bruno A. M. Huang J. Y. Bennett D. A. Marr R. A. Hastings M. L. Stutzmann G. E.   (2012 ). Altered ryanodine receptor
expression in mild cognitive impairment and Alzheimer’s
disease. 
Neurobiol Aging , 33 (5 ),
1001.e1–1001.e6.
doi:10.1016/J.NEUROBIOLAGING.2011.03.011
Buisson A. Callebert J. Mathieu E. Plotkine M. Boulu R. G.   (1992 ). Striatal protection induced
by lesioning the substantia nigra of rats subjected to focal
ischemia. 
J Neurochem , 59 (3 ),
1153 –1157 . Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/13537891353789 
Buisson A. Choi D. W.   (1995 ). The inhibitory mGluR
agonist, S-4-carboxy-3-hydroxy-phenylglycine selectively attenuates NMDA
neurotoxicity and oxygen-glucose deprivation-induced neuronal
death. 
Neuropharmacology , 34 (8 ),
1081 –1087 . Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/85321578532157 
Busche M. A. Chen X. Henning H. A. Reichwald J. Staufenbiel M. Sakmann B. Konnerth A.   (2012 ). Critical role of soluble
amyloid-β for early hippocampal hyperactivity in a mouse model of
Alzheimer’s disease. 
Proc Natl Acad Sci U S A ,
109 (22 ),
8740 –8745 .
doi:10.1073/pnas.120617110922592800 
Butterfield D. A. Castegna A. Lauderback C. M. Drake J.   (2002 ). Evidence that amyloid
beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s
disease brain contribute to neuronal death. 
Neurobiol Aging , 23 (5 ),
655 –664 . Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1239276612392766 
Butterfield D. A. Pocernich C. B.   (2003 ). The glutamatergic system and
Alzheimer’s disease. 
CNS Drugs , 17 (9 ),
641 –652 .
doi:10.2165/00023210-200317090-0000412828500 
Calabresi P. Pisani A. Mercuri N. B. Bernardi G.   (1992 ). Long-term potentiation in
the striatum is unmasked by removing the voltage-dependent magnesium block
of NMDA receptor channels. 
Eur J Neurosci , 4 (10 ),
929 –935 .
doi:10.1111/j.1460-9568.1992.tb00119.x12106428 
Canas, P. M., Simoes, A. P., Rodrigues,
R. J., Cunha, R. A. (2014). Predominant loss of glutamatergic terminal markers
in a β-amyloid peptide model of Alzheimer’s disease. Neuropharmacology,
76(A), 51–56. doi:10.1016/j.neuropharm.2013.08.026
Cassano T. Serviddio G. Gaetani S. Romano A. Dipasquale P. Cianci S. Bellanti F. Laconca L. Romano A. D. Padalino I. LaFerla F. M. Nicoletti F. Cuomo V. Vendemiale G.   (2012 ). Glutamatergic alterations
and mitochondrial impairment in a murine model of Alzheimer
disease. 
Neurobiol Aging , 33 (6 ),
1121.e1–1121.e12.
doi:10.1016/J.NEUROBIOLAGING.2011.09.021
Chen L. Wang H. Zhang Z. Li Z. He D. Sokabe M. Chen L.   (2010 ). DMXB (GTS-21) ameliorates
the cognitive deficits in beta amyloid(25-35) injected mice through
preventing the dysfunction of alpha7 nicotinic receptor. 
J Neurosci Res , 88 (8 ),
1784 –1794 .
doi:10.1002/jnr.2234520127813 
Chen L. Yamada K. Nabeshima T. Sokabe M.   (2006 ). α7 Nicotinic acetylcholine
receptor as a target to rescue deficit in hippocampal LTP induction in
β-amyloid infused rats. 
Neuropharmacology , 50 (2 ),
254 –268 .
doi:10.1016/j.neuropharm.2005.09.01816324726 
Chen Q.-S. Wei W.-Z. Shimahara T. Xie C.-W.   (2002 ). Alzheimer amyloid β-peptide
inhibits the late phase of long-term potentiation through
calcineurin-dependent mechanisms in the hippocampal dentate
gyrus. 
Neurobiol Learn Mem , 77 (3 ),
354 –371 .
doi:10.1006/nlme.2001.403411991763 
Cleary J. P. Walsh D. M. Hofmeister J. J. Shankar G. M. Kuskowski M. A. Selkoe D. J. Ashe K. H.   (2005 ). Natural oligomers of the
amyloid-β protein specifically disrupt cognitive function. 
Nat Neurosci , 8 (1 ),
79 –84 . doi:10.1038/nn137215608634 
Clements J. D. Lester R. A. Tong G. Jahr C. E. Westbrook G. L.   (1992 ). The time course of glutamate
in the synaptic cleft. 
Science (New York, N.Y.) ,
258 (5087 ),
1498 –1501 . Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1359647
Collingridge G. L. Bliss T. V.   (1995 ). Memories of NMDA receptors
and LTP. 
Trend Neurosci , 18 (2 ),
54 –56 . Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/75374067537406 
D’Andrea M. Nagele R.   (2006 ). Targeting the alpha 7
nicotinic acetylcholine receptor to reduce amyloid accumulation in
Alzheimers disease pyramidal neurons. 
Curr Pharm Des , 12 (6 ),
677 –684 .
doi:10.2174/13816120677547422416472157 
D’Andrea M. R. Nagele R. G. Wang H. Y. Peterson P. A. Lee D. H.   (2001 ). Evidence that neurones
accumulating amyloid can undergo lysis to form amyloid plaques in
Alzheimer’s disease. 
Histopathology , 38 (2 ),
120 –134 . Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1120782511207825 
Danysz W. Parsons C. G.   (2012 ). Alzheimer’s disease,
β-amyloid, glutamate, NMDA receptors and memantine – Searching for the
connections. 
Br J Pharmacol , 167 (2 ),
324 –352 .
doi:10.1111/j.1476-5381.2012.02057.x22646481 
Davis S. Butcher S. P. Morris R. G.   (1992 ). The NMDA receptor antagonist
D-2-amino-5-phosphonopentanoate (D-AP5) impairs spatial learning and LTP in
vivo at intracerebral concentrations comparable to those that block LTP in
vitro. 
J Neurosci , 12 (1 ),
21 –34 . Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/13459451345945 
De Felice F. G. Velasco P. T. Lambert M. P. Viola K. Fernandez S. J. Ferreira S. T. Klein W. L.   (2007 ). Aβ oligomers induce neuronal
oxidative stress through an N-methyl-D-aspartate receptor-dependent
mechanism that is blocked by the Alzheimer drug memantine. 
J Biol Chem , 282 (15 ),
11590 –11601 .
doi:10.1074/jbc.M60748320017308309 
Decker H. Lo K. Y. Unger S. M. Ferreira S. T. Silverman M. A.   (2010 ). Amyloid-β peptide oligomers
disrupt axonal transport through an NMDA receptor-dependent mechanism that
is mediated by glycogen synthase kinase 3beta in primary cultured
hippocampal neurons . J Neurosci ,
30 (27 ),
9166 –9171 .
doi:10.1523/jneurosci.1074-10.201020610750 
DeKosky S. T. Scheff S. W.   (1990 ). Synapse loss in frontal
cortex biopsies in Alzheimer’s disease: Correlation with cognitive
severity. 
Ann Neurol , 27 (5 ),
457 –464 .
doi:10.1002/ana.4102705022360787 
Deutsch S. I. Burket J. A. Benson A. D.   (2014 ). Targeting the α7 nicotinic
acetylcholine receptor to prevent progressive dementia and improve cognition
in adults with Down’s syndrome. 
Prog Neuropsychopharmacol Biol Psychiatry , 54 ,
131 –139 .
doi:10.1016/J.PNPBP.2014.05.01124865150 
Dewar D. Chalmers D. T. Graham D. I. McCulloch J.   (1991 ). Glutamate metabotropic and
AMPA binding sites are reduced in Alzheimer’s disease: An autoradiographic
study of the hippocampus. 
Brain Res , 553 (1 ),
58 –64 .
doi:10.1016/0006-8993(91)90230-S1933277 
Dias C. Lourenço C. F. Ferreiro E. Barbosa R. M. Laranjinha J. Ledo A.   (2016 ). Age-dependent changes in the
glutamate-nitric oxide pathway in the hippocampus of the triple transgenic
model of Alzheimer’s disease: Implications for neurometabolic
regulation. 
Neurobiol Aging , 46 ,
84 –95 .
doi:10.1016/J.NEUROBIOLAGING.2016.06.01227460153 
Dineley K. T. Bell K. A. Bui D. Sweatt J. D.   (2002 a). β- Amyloid peptide
activates α7 nicotinic acetylcholine receptors expressed in
Xenopus oocytes. 
J Biol Chem , 277 (28 ),
25056 –25061 .
doi:10.1074/jbc.M20006620011983690 
Dineley K. T. Westerman M. Bui D. Bell K. Ashe K. H. Sweatt J. D.   (2001 ). Beta-amyloid activates the
mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic
acetylcholine receptors: In vitro and in vivo mechanisms related to
Alzheimer’s disease. 
J Neurosci , 21 (12 ),
4125 –4133 . Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1140439711404397 
Dineley K. T. Xia X. Bui D. Sweatt J. D. Zheng H.   (2002 b). Accelerated plaque
accumulation, associative learning deficits, and up-regulation of alpha 7
nicotinic receptor protein in transgenic mice co-expressing mutant human
presenilin 1 and amyloid precursor proteins. 
J Biol Chem , 277 (25 ),
22768 –22780 .
doi:10.1074/jbc.M20016420011912199 
Dougherty J. J. Wu J. Nichols R. A.   (2003 ). Beta-amyloid regulation of
presynaptic nicotinic receptors in rat hippocampus and
neocortex. 
J Neurosci , 23 (17 ),
6740 –6747 . Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1289076612890766 
Esposito Z. Belli L. Toniolo S. Sancesario G. Bianconi C. Martorana A.   (2013 ). Amyloid β, glutamate,
excitotoxicity in Alzheimer’s disease: Are we on the right
track? 
CNS Neurosci Ther , 19 (8 ),
549 –555 .
doi:10.1111/cns.1209523593992 
Ferraguti F. Baldani-Guerra B. Corsi M. Nakanishi S. Corti C.   (1999 ). Activation of the
extracellular signal-regulated kinase 2 by metabotropic glutamate
receptors. 
Eur J Neurosci , 11 (6 ),
2073 –2082 .
doi:10.1046/j.1460-9568.1999.00626.x10336676 
Ferraguti F. Shigemoto R.   (2006 ). Metabotropic glutamate
receptors. 
Cell Tissue Res , 326 (2 ),
483 –504 .
doi:10.1007/s00441-006-0266-516847639 
Ferreira S. T. Klein W. L.   (2011 ). The Aβ oligomer hypothesis
for synapse failure and memory loss in Alzheimer’s disease. 
Neurobiol Learn Mem , 96 (4 ),
529 –543 .
doi:10.1016/j.nlm.2011.08.00321914486 
Fremeau R. T. Kam K. Qureshi T. Johnson J. Copenhagen D. R. Storm-Mathisen J. Chaudhry F. A. Nicoll R. A. Edwards R. H.   (2004 ). Vesicular glutamate
transporters 1 and 2 target to functionally distinct synaptic release
sites. 
Science , 304 (5678 ),
1815 –1819 .
doi:10.1126/science.109746815118123 
Fremeau R. T. Troyer M. D. Pahner I. Nygaard G. O. Tran C. H. Reimer R. J. Bellocchio E. E. Fortin D. Storm-Mathisen J. Edwards R. H.   (2001 ). The expression of vesicular
glutamate transporters defines two classes of excitatory
synapse. 
Neuron , 31 (2 ),
247 –260 . Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1150225611502256 
Gahring L. C. Persiyanov K. Dunn D. Weiss R. Meyer E. L. Rogers S. W.   (2004 ). Mouse strain-specific
nicotinic acetylcholine receptor expression by inhibitory interneurons and
astrocytes in the dorsal hippocampus. 
J Comp Neurol , 468 (3 ),
334 –346 .
doi:10.1002/cne.1094314681929 
Garthwaite J. Garthwaite G. Palmer R. M. J. Moncada S.   (1989 ). NMDA receptor activation
induces nitric oxide synthesis from arginine in rat brain
slices. 
Eur J Pharmacol , 172 (4–5 ),
413 –416 .
doi:10.1016/0922-4106(89)90023-02555211 
Godyń J. Jończyk J. Panek D. Malawska B.   (2016 ). Therapeutic strategies for
Alzheimer’s disease in clinical trials. 
Pharmacol Rep , 68 (1 ),
127 –138 .
doi:10.1016/J.PHAREP.2015.07.00626721364 
Goussakov I. Miller M. B. Stutzmann G. E.   (2010 ). NMDA-mediated Ca(2+) influx
drives aberrant ryanodine receptor activation in dendrites of young
Alzheimer’s disease mice. 
J Neurosci , 30 (36 ),
12128 –12137 .
doi:10.1523/JNEUROSCI.2474-10.201020826675 
Gray C. W. Patel A. J.   (1995 ). Neurodegeneration mediated
by glutamate and beta-amyloid peptide: A comparison and possible
interaction. 
Brain Res , 691 (1–2 ),
169 –179 . Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/85900498590049 
Gray R. Rajan A. S. Radcliffe K. A. Yakehiro M. Dani J. A.   (1996 ). Hippocampal synaptic
transmission enhanced by low concentrations of nicotine. 
Nature , 383 (6602 ),
713 –716 . doi:10.1038/383713a08878480 
Groc L. Bard L. Choquet D.   (2009 ). Surface trafficking of
N-methyl-d-aspartate receptors: Physiological and pathological
perspectives. 
Neuroscience , 158 (1 ),
4 –18 .
doi:10.1016/j.neuroscience.2008.05.02918583064 
Grutzendler J. Helmin K. Tsai J. Gan W. B.   (2007 ). Various dendritic
abnormalities are associated with fibrillar amyloid deposits in Alzheimer’s
disease. 
Ann N Y Acad Sci , 1097 (1 ),
30 –39 .
doi:10.1196/annals.1379.00317413007 
Gu Z. Liu W. Yan Z.   (2009 ). Amyloid impairs AMPA
receptor trafficking and function by reducing
Ca2+/calmodulin-dependent protein kinase II synaptic
distribution. 
J Biol Chem , 284 (16 ),
10639 –10649 .
doi:10.1074/jbc.M80650820019240035 
Gu Z. Yakel J. L.   (2011 ). Timing-dependent septal
cholinergic induction of dynamic hippocampal synaptic
plasticity. 
Neuron , 71 (1 ),
155 –165 .
doi:10.1016/j.neuron.2011.04.02621745645 
Hardingham G. E. Bading H.   (2003 ). The Yin and Yang of NMDA
receptor signalling. 
Trend Neurosci , 26 (2 ),
81 –89 .
doi:10.1016/S0166-2236(02)00040-112536131 
Hardingham G. E. Fukunaga Y. Bading H.   (2002 ). Extrasynaptic NMDARs oppose
synaptic NMDARs by triggering CREB shut-off and cell death
pathways. 
Nat Neurosci , 5 (5 ),
405 –414 . doi:10.1038/nn83511953750 
Haris M. Nath K. Cai K. Singh A. Crescenzi R. Kogan F. Verma G. Reddy S. Hariharan H. Melhem E. R. Reddy R.   (2013 ). Imaging of glutamate
neurotransmitter alterations in Alzheimer’s disease. 
NMR Biomed , 26 :
386 –391 . doi:10.1002/nbm.287523045158 
Hascup E. R. Broderick S. O. Russell M. K. Fang Y. Bartke A. Boger H. A. Hascup K. N.   (2019 a). Diet‐induced insulin
resistance elevates hippocampal glutamate as well as VGLUT1 and GFAP
expression in AβPP/PS1 mice. 
J Neurochem , 148 ,
219 –237 .
doi:10.1111/jnc.14490.30472734 
Hascup E. R. Hascup K. N. Stephens M. Pomerleau F. Huettl P. Gratton A. Gerhardt G. A.   (2010 ). Rapid microelectrode
measurements and the origin and regulation of extracellular glutamate in rat
prefrontal cortex. 
J Neurochem , 115 (6 ),
1608 –1620 .
doi:10.1111/j.1471-4159.2010.0706620969570 
Hascup K. N. Britz J. Findley C. A. Tischkau S. Hascup E. R.   (2019 b). LY379268 does not have
long-term procognitive effects nor attenuate glutamatergic signaling in
AβPP/PS1 mice. 
J Alzheimers Dis , 68 (3 ),
1193 –1209 .
doi:10.3233/JAD-18123130909243 
Hascup K. N. Broderick S. O. Hascup E. R.   (2016 ). Can Alzheimer’s-Related
Cognitive Decline Be Delayed Through Prodromal Treatment? Evidence from a
mouse model of Alzheimer’s disease. 
Alzheimers Dement , 12 (7 ),
P1017 . doi:10.1016/j.jalz.2016.06.2097
Hascup K. N. Hascup E. R.   (2015 ). Altered neurotransmission
prior to cognitive decline in AβPP/PS1 mice, a model of Alzheimer’s
disease. 
J Alzheimers Dis , 44 ,
771 –776 .
doi:10.3233/JAD-14216025374106 
Hascup K. N. Hascup E. R.   (2016 ). Soluble amyloid-β42
stimulates glutamate release through activation of the α7 nicotinic
acetylcholine receptor. 
J Alzheimers Dis , 53 ,
337 –347 .
doi:10.3233/JAD-16004127163813 
Hefendehl J. K. LeDue J. Ko R. W. Y. Mahler J. Murphy T. H. MacVicar B. A.   (2016 ). Mapping synaptic glutamate
transporter dysfunction in vivo to regions surrounding Aβ plaques by
iGluSnFR two-photon imaging . Nat Commun ,
7 (1 ), 13441 .
doi:10.1038/ncomms1344127834383 
Hellström-Lindahl E. Mousavi M. Zhang X. Ravid R. Nordberg A.   (1999 ). Regional distribution of
nicotinic receptor subunit mRNAs in human brain: Comparison between
Alzheimer and normal brain. 
Brain Res , 66 (1–2 ),
94 –103 . Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10095081
Hellweg R. Wirth Y. Janetzky W. Hartmann S.   (2012 ). Efficacy of memantine in
delaying clinical worsening in Alzheimer’s disease (AD): Responder analyses
of nine clinical trials with patients with moderate to severe
AD. 
Int J Geriatr Psychiatry ,
27 (6 ), 651 –656 .
doi:10.1002/gps.276622513699 
Hiruma H. Katakura T. Takahashi S. Ichikawa T. Kawakami T.   (2003 ). Glutamate and amyloid
beta-protein rapidly inhibit fast axonal transport in cultured rat
hippocampal neurons by different mechanisms. 
J Neurosci , 23 (26 ),
8967 –8977 .
doi:10.1523/JNEUROSCI.23-26-08967.200314523099 
Hoey S. E. Williams R. J. Perkinton M. S.   (2009 ). Synaptic NMDA receptor
activation stimulates α-secretase amyloid precursor protein processing and
inhibits amyloid-β production. 
J Neurosci , 29 (14 ),
4442 –4460 .
doi:10.1523/JNEUROSCI.6017-08.200919357271 
Hof P. R. Bussière T. Gold G. Kövari E. Giannakopoulos P. Bouras C. Perl D. P. Morrison J. H.   (2003 ). Stereologic evidence for
persistence of viable neurons in layer II of the entorhinal cortex and the
CA1 field in Alzheimer disease. 
J Neuropathol Exp Neurol ,
62 (1 ), 55 –67 .
doi:10.1093/jnen/62.1.5512528818 
Huang, W., Zhang X., Chen, W. (2016).
Role of oxidative stress in Alzheimer’s disease. Biomed Rep,
4(5), 519–522. doi:10.3892/br.2016.630
Huijbers W. Mormino E. C. Schultz A. P. Wigman S. Ward A. M. Larvie M. Amariglio R. E. Marshall G. A. Rentz D. M. Johnson K. A. Sperling R. A.   (2015 ). Amyloid-β deposition in mild
cognitive impairment is associated with increased hippocampal activity,
atrophy and clinical progression. 
Brain , 138 (4 ),
1023 –1035 .
doi:10.1093/brain/awv00725678559 
Hyman B. T. Marzloff K. Wenniger J. J. Dawson T. M. Bredt D. S. Snyder S. H.   (1992 ). Relative sparing of nitric
oxide synthase-containing neurons in the hippocampal formation in
Alzheimer’s disease. 
Ann Neurol , 32 (6 ),
818 –820 .
doi:10.1002/ana.4103206181281971 
Hynd M. R. Scott H. L. Dodd P. R.   (2004 a). Differential expression of
N-methyl-D-aspartate receptor NR2 isoforms in Alzheimer’s
disease. 
J Neurochem , 90 (4 ),
913 –919 .
doi:10.1111/j.1471-4159.2004.02548.x15287897 
Hynd M. R. Scott H. L. Dodd P. R.   (2004 b). Selective loss of NMDA
receptor NR1 subunit isoforms in Alzheimer’s disease. 
J Neurochem , 89 (1 ),
240 –247 .
doi:10.1111/j.1471-4159.2003.02330.x15030408 
Imre G.   (2007 ). The preclinical properties
of a novel group II metabotropic glutamate receptor agonist
LY379268. 
CNS Drug Reviews , 13 (4 ),
444 –464 
doi:10.1111/j.1527-3458.2007.00024.x18078428 
Isaac J. T. R. Ashby M. C. McBain C. J.   (2007 ). The role of the GluR2
subunit in AMPA receptor function and synaptic plasticity. 
Neuron , 54 (6 ),
859 –871 .
doi:10.1016/J.NEURON.2007.06.00117582328 
Jacob C. P. Koutsilieri E. Bartl J. Neuen-Jacob E. Arzberger T. Zander N. Roggendorf W. Riederer P. Grünblatt E.   (2007 ). Alterations in expression of
glutamatergic transporters and receptors in sporadic Alzheimer’s
disease. 
J Alzheimers Dis , 11 (1 ),
97 –116 .
doi:10.3233/JAD-2007-1111317361039 
Kashani A. Lepicard È. Poirel O. Videau C. David J. P. Fallet-Bianco C. Simon A. Delacourte A. Giros B. Epelbaum J. Betancur C. El Mestikawy S.   (2008 ). Loss of VGLUT1 and VGLUT2 in
the prefrontal cortex is correlated with cognitive decline in Alzheimer
disease. 
Neurobiol Aging , 29 ,
1619 –1630 .
doi:10.1016/j.neurobiolaging.2007.04.01017531353 
Katagiri H. Tanaka K. Manabe T.   (2001 ). Requirement of appropriate
glutamate concentrations in the synaptic cleft for hippocampal LTP
induction. 
Eu rJ Neurosci , 14 (3 ),
547 –553 . Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11553304
Kervern M. Angeli A. Nicole O. Léveillé F. Parent B. Villette V. Buisson A. Dutar P.   (2012 ). Selective impairment of some
forms of synaptic plasticity by oligomeric amyloid-β peptide in the mouse
hippocampus: Implication of extrasynaptic NMDA receptors. 
J Alzheimers Dis , 32 (1 ),
183 –196 .
doi:10.3233/JAD-2012-12039422785392 
Kishida K. T. Klann E.   (2006 ). Sources and targets of
reactive oxygen species in synaptic plasticity and memory. 
Antioxid Redox Signal , 9 (2 ),
233 –244 .
doi:10.1089/ars.2007.9.233
Knight E. M. Martins I. V. A. Gümüsgöz S. Allan S. M. Lawrence C. B.   (2014 ). High-fat diet-induced memory
impairment in triple-transgenic Alzheimer’s disease (3xTgAD) mice is
independent of changes in amyloid and tau pathology. 
Neurobiol Aging , 35 (8 ),
1821 –1832 .
doi:10.1016/J.NEUROBIOLAGING.2014.02.01024630364 
Koh J. Y. Yang L. L. Cotman C. W.   (1990 ). Beta-amyloid protein
increases the vulnerability of cultured cortical neurons to excitotoxic
damage. 
Brain Res , 533 (2 ),
315 –320 . Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/22891452289145 
Konradsson-Geuken A. Gash C. R. Alexander K. Pomerleau F. Huettl P. Gerhardt G. A. Bruno J. P.   (2009 ). Second-by-second analysis of
alpha 7 nicotine receptor regulation of glutamate release in the prefrontal
cortex of awake rats . Synapse ,
63 (12 ),
1069 –1082 .
doi:10.1002/syn.2069319637277 
Kopeikina K. J. Hyman B. T. Spires-Jones T. L.   (2012 ). Soluble forms of tau are
toxic in Alzheimer’s disease . Transl
Neurosci , 3 (3 ),
223 –233 .
doi:10.2478/s13380-012-0032-y23029602 
Lacor P. N. Buniel M. C. Furlow P. W. Sanz Clemente A. Velasco P. T. Wood M. Viola K. L. Klein W. L.   (2007 ). Aβ oligomer-induced
aberrations in synapse composition, shape, and density provide a molecular
basis for loss of connectivity in Alzheimer’s disease. 
J Neurosci , 27 (4 ),
796 –807 .
doi:10.1523/JNEUROSCI.3501-06.200717251419 
Lambe E. K. Picciotto M. R. Aghajanian G. K.   (2003 ). Nicotine induces glutamate
release from thalamocortical terminals in prefrontal cortex. 
Neuropsychopharmacology , 28 (2 ),
216 –225 .
doi:10.1038/sj.npp.130003212589374 
Law A. Gauthier S. Quirion R.   (2001 ). Say NO to Alzheimer’s
disease: The putative links between nitric oxide and dementia of the
Alzheimer’s type. 
Brain Res Rev , 35 (1 ),
73 –96 .
doi:10.1016/S0165-0173(00)00051-511245887 
Lee H. Ogawa O. Zhu X. O’Neill M. J. Petersen R. B. Castellani R. J. Ghanbari H. Perry G. Smith M. A.   (2004 ). Aberrant expression of
metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimer’s
disease. 
Acta Neuropathol , 107 (4 ),
365 –371 .
doi:10.1007/s00401-004-0820-814872255 
Lee H. Zhu X. Casadesus G. Pallàs M. Camins A. O’Neill M. J. Nakanishi S. Perry G. Smith M. A.   (2009 ). The effect of mGluR2
activation on signal transduction pathways and neuronal cell
survival. 
Brain Res , 1249 ,
244 –250 .
doi:10.1016/J.BRAINRES.2008.10.05519026996 
Lehre K. P. Levy L. M. Ottersen O. P. Storm-Mathisen J. Danbolt N. C.   (1995 ). Differential expression of
two glial glutamate transporters in the rat brain: Quantitative and
immunocytochemical observations. 
J Neurosci , 15 (3 ),
1835 –1853 .
doi:10.1523/JNEUROSCI.15-03-01835.19957891138 
Lesné S. Ali C. Gabriel C. Croci N. Mackenzie E. T. Glabe C. G. Plotkine M. Marchand-Verrecchia C. Vivien D. Buisson A.   (2005 ). NMDA receptor activation
inhibits-secretase and promotes neuronal amyloid-production .
J Neurosci , 25 (41 ),
9367 –9377 .
doi:10.1523/JNEUROSCI.0849-05.200516221845 
Li S. Jin M. Koeglsperger T. Shepardson N. E. Shankar G. M. Selkoe D. J.   (2011 ). Soluble Aβ oligomers inhibit
long-term potentiation through a mechanism involving excessive activation of
extrasynaptic NR2B-containing NMDA receptors. 
J Neurosci , 31 (18 ),
6627 –6638 .
doi:10.1523/JNEUROSCI.0203-11.201121543591 
Lin H. Vicini S. Hsu F.-C. Doshi S. Takano H. Coulter D. A. Lynch D. R.   (2010 ). Axonal α7 nicotinic ACh
receptors modulate presynaptic NMDA receptor expression and structural
plasticity of glutamatergic presynaptic boutons. 
Proc Natl Acad Sci U S A .,
107 (38 ),
16661 –16666 .
doi:10.1073/pnas.100739710720817852 
Liu Q.-S. Kawai H. Berg D. K.   (2001 ). β-Amyloid peptide blocks the
response of 7-containing nicotinic receptors on hippocampal
neurons. 
Proc Natl Acad Sci , 98 (8 ),
4734 –4739 .
doi:10.1073/pnas.08155359811274373 
Lu Z. Xu S.   (2006 ). ERK1/2 MAP kinases in cell
survival and apoptosis. 
IUBMB Life , 58 (11 ),
621 –631 .
doi:10.1080/1521654060095743817085381 
Magdesian M. H. Nery A. A. Martins A. H. B. Juliano M. A. Juliano L. Ulrich H. Ferreira S. T.   (2005 ). Peptide blockers of the
inhibition of neuronal nicotinic acetylcholine receptors by amyloid
β. 
J Biol Chem , 280 (35 ),
31085 –31090 .
doi:10.1074/jbc.M50240620015987688 
Manzoni O. Prezeau L. Marin P. Deshager S. Bockaert J. Fagni L.   (1992 ). Nitric oxide-induced
blockade of NMDA receptors. 
Neuron , 8 (4 ),
653 –662 .
doi:10.1016/0896-6273(92)90087-T1314618 
Marchi M. Risso F. Viola C. Cavazzani P. Raiteri M.   (2002 ). Direct evidence that
release-stimulating alpha7* nicotinic cholinergic receptors are localized on
human and rat brain glutamatergic axon terminals. 
J Neurochem , 80 (6 ),
1071 –1078 .
doi:10.1046/j.0022-3042.2002.00805.x11953457 
Martinez-Coria H. Green K. N. Billings L. M. Kitazawa M. Albrecht M. Rammes G. Parsons C. G. Gupta S. Banerjee P. LaFerla F. M.   (2010 ). Memantine improves cognition
and reduces Alzheimer’s-like neuropathology in transgenic
mice. 
Am J Pathol , 176 (2 ),
870 –880 .
doi:10.2353/AJPATH.2010.09045220042680 
Martinsson I. Capetillo-Zarate E. Faideau M. Willén K. Esteras N. Frykman S. Tjernberg L. O. Gouras G. K.   (2019 ). APP depletion alters
selective pre- and post-synaptic proteins. 
Mol Cell Neurosci , 95 ,
86 –95 .
doi:10.1016/j.mcn.2019.02.00330763689 
Masliah E. Mallory M. Hansen L. Alford M. DeTeresa R. Terry R.   (1993 ). An antibody against
phosphorylated neurofilaments identifies a subset of damaged association
axons in Alzheimer’s disease . Am J Pathol ,
142 (3 ),
871 –882 . Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/84569468456946 
McShane R. Areosa Sastre A. Minakaran N.   (2006 ). Memantine for
dementia . Cochrane Database Syst Rev ,
2 (2 ), CD003154 .
doi:10.1002/14651858.CD003154.pub5
Miller S. L. Fenstermacher E. Bates J. Blacker D. Sperling R. A. Dickerson B. C.   (2008 ). Hippocampal activation in
adults with mild cognitive impairment predicts subsequent cognitive
decline. 
J Neurol Neurosurg Psychiatry ,
79 (6 ),
630 –635 .
doi:10.1136/jnnp.2007.12414917846109 
Minkeviciene R. Ihalainen J. Malm T. Matilainen O. Keksa-Goldsteine V. Goldsteins G. Iivonen H. Leguit N. Glennon J. Koistinaho J. Banerjee P. Tanila H.   (2008 ). Age-related decrease in
stimulated glutamate release and vesicular glutamate transporters in APP/PS1
transgenic and wild-type mice. 
J Neurochem , 105 (3 ),
584 –594 .
doi:10.1111/j.1471-4159.2007.05147.x18042177 
Mitani A. Andou Y. Kataoka K.   (1992 ). Selective vulnerability of
hippocampal CA1 neurons cannot be explained in terms of an increase in
glutamate concentration during ischemia in the gerbil: Brain microdialysis
study. 
Neuroscience , 48 (2 ),
307 –313 . Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/13512671351267 
Mookherjee P. Green P. S. Watson G. S. Marques M. A. Tanaka K. Meeker K. D. Meabon James S. Li N. Zhu P. Olson V. G. Cook D. G.   (2011 ). GLT-1 loss accelerates
cognitive deficit onset in an Alzheimer’s disease animal
model. 
J Alzheimers Dis , 26 (3 ),
447 –455 .
doi:10.3233/JAD-2011-11050321677376 
Morales I. Guzmán-Martínez L. Cerda-Troncoso C. Farías G. A. Maccioni R. B.   (2014 ). Neuroinflammation in the
pathogenesis of Alzheimer’s disease. A rational framework for the search of
novel therapeutic approaches. 
Front Cell Neurosci , 8 , 112 .
doi:10.3389/fncel.2014.0011224795567 
Mura E. Zappettini S. Preda S. Biundo F. Lanni C. Grilli M. Cavallero A. Olivero G. Salamone A. Marchi M.   (2012 ). Dual effect of beta-amyloid
on α7 and α4β2 nicotinic receptors controlling the release of glutamate,
aspartate and GABA in rat hippocampus. 
PLoS One , 7 (1 ),
e29661 . doi:10.1371/journal.pone.002966122253754 
Nagele R. G. D’Andrea M. R. Anderson W. J. Wang H.-Y.   (2002 ). Intracellular accumulation
of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic
acetylcholine receptor in Alzheimer’s disease. 
Neuroscience , 110 (2 ),
199 –211 . Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1195886311958863 
Nagele R. G. Wegiel J. Venkataraman V. Imaki H. Wang K.-C. Wegiel J.   (2004 ). Contribution of glial cells
to the development of amyloid plaques in Alzheimer’s
disease. 
Neurobiol Aging , 25 (5 ),
663 –674 .
doi:10.1016/j.neurobiolaging.2004.01.00715172746 
Näslund J. Schierhorn A. Hellman U. Lannfelt L. Roses A. D. Tjernberg L. O. Silberring J. Gandy S. E. Winblad B. Greengard P.   (1994 ). Relative abundance of
Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal
aging. 
Proc Natl Acad Sci U S A .,
91 (18 ),
8378 –8382 .
doi:10.1073/PNAS.91.18.83788078890 
Newpher T. M. Ehlers M. D.   (2009 ). Spine microdomains for
postsynaptic signaling and plasticity. 
Trends Cell Biol , 19 (5 ),
218 –227 .
doi:10.1016/j.tcb.2009.02.00419328694 
Neyman S. Manahan-Vaughan D.   (2008 ). Metabotropic glutamate
receptor 1 (mGluR1) and 5 (mGluR5) regulate late phases of LTP and LTD in
the hippocampal CA1 region in vitro. 
Eur J Neurosci , 27 (6 ),
1345 –1352 .
doi:10.1111/j.1460-9568.2008.06109.x18364018 
Nicolle M. M. Gonzalez J. Sugaya K. Baskerville K. A. Bryan D. Lund K. Gallagher M. McKinney M.   (2001 ). Signatures of hippocampal
oxidative stress in aged spatial learning-impaired rodents. 
Neuroscience , 107 (3 ),
415 –431 .
doi:10.1016/S0306-4522(01)00374-811718997 
Norenberg M. D. Martinez-Hernandez A.   (1979 ). Fine structural localization
of glutamine synthetase in astrocytes of rat brain. 
Brain Res , 161 (2 ),
303 –310 . Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/3196631966 
O’Brien J. L. O’Keefe K. M. LaViolette P. S. DeLuca A. N. Blacker D. Dickerson B. C. Sperling R. A.   (2010 ). Longitudinal fMRI in elderly
reveals loss of hippocampal activation with clinical
decline. 
Neurology , 74 (24 ),
1969 –1976 .
doi:10.1212/WNL.0b013e3181e3966e20463288 
Okonkwo O. C. Oh J. M. Koscik R. Jonaitis E. Cleary C. A. Dowling N. M. Bendlin B. B. Larue A. Hermann B. P. Barnhart T. E. Murali D. Rowley H. A. Carlsson C. M. Gallagher C. L. Asthana S. Sager M. A. Christian B. T. Johnson S. C.   (2014 ). Amyloid burden, neuronal
function, and cognitive decline in middle-aged adults at risk for
Alzheimer’s disease. 
J Int Neuropsychol Soc , 20 (4 ),
422 –433 .
doi:10.1017/S135561771400011324621494 
Olabarria M. Noristani H. N. Verkhratsky A. Rodríguez J. J.   (2010 ). Concomitant astroglial
atrophy and astrogliosis in a triple transgenic animal model of Alzheimer’s
disease . Glia ,
58 (7 ),
831 –838 . doi:10.1002/glia.2096720140958 
Olabarria M. Noristani H. N. Verkhratsky A. Rodríguez J. J.   (2011 ). Age-dependent decrease in
glutamine synthetase expression in the hippocampal astroglia of the triple
transgenic Alzheimer’s disease mouse model: Mechanism for deficient
glutamatergic transmission? 
Mol Neurodegener , 6 , 55 .
doi:10.1186/1750-1326-6-5521801442 
Olney J. W. Wozniak D. F. Farber N. B.   (1997 ). Excitotoxic
neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic
strategies . Arch Neurol ,
54 (10 ),
1234 –1240 . Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/93415699341569 
Ovsepian S. V OLeary V. B. Zaborszky L. Ntziachristos V. Oliver Dolly J.   (2018 ). Amyloid plaques of
Alzheimer’s disease as hotspots of glutamatergic activity. 
Neuroscientist , 0 ,
1 –2 .
doi:10.1177/1073858418791128
Palmieri E. M. Menga A. Lebrun A. Hooper D. C. Butterfield D. A. Mazzone M. Castegna A.   (2017 ). Blockade of glutamine
synthetase enhances inflammatory response in microglial
cells. 
Antioxid Redox Signal , 26 (8 ),
351 –363 .
doi:10.1089/ars.2016.671527758118 
Palop J. J. Mucke L.   (2010 ). Amyloid-β–induced neuronal
dysfunction in Alzheimer’s disease: From synapses toward neural
networks. 
NatNeurosci , 13 (7 ),
812 –818 . doi:10.1038/nn.2583
Pandis C. Sotiriou E. Kouvaras E. Asprodini E. Papatheodoropoulos C. Angelatou F.   (2006 ). Differential expression of
NMDA and AMPA receptor subunits in rat dorsal and ventral
hippocampus. 
Neuroscience , 140 (1 ),
163 –175 .
doi:10.1016/J.NEUROSCIENCE.2006.02.00316542781 
Parameshwaran K. Sims C. Kanju P. Vaithianathan T. Shonesy B. C. Dhanasekaran M. Bahr B. A. Suppiramaniam V.   (2007 ). Amyloid β-peptide Aβ1–42 but
not Aβ1–40 attenuates synaptic AMPA receptor function. 
Synapse , 61 (6 ),
367 –374 .
doi:10.1002/syn.2038617372971 
Parks J. K. Smith T. S. Trimmer P. A. Bennett J. P. Parker W. D.   (2001 ). Neurotoxic Aβ peptides
increase oxidative stress in vivo through NMDA-receptor and
nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce
a mitochondrial permeability transition in vitro. 
J Neurochem , 76 (4 ),
1050 –1056 .
doi:10.1046/j.1471-4159.2001.00112.x11181824 
Parri H. R. Hernandez C. M. Dineley K. T.   (2011 ). Research update: Alpha7
nicotinic acetylcholine receptor mechanisms in Alzheimer’s
disease. 
Biochem Pharmacol , 82 ,
931 –942 .
doi:10.1016/j.bcp.2011.06.03921763291 
Parsons C. G. Albrecht M. Rammes G.   (2009 ). Memantine reverses ß-amyloid
oligomers-induced deficits in long term potentiation (LTP) in murine
hippocampal slices. 
Alzheimers Dement , 5 (4 ),
P176 . doi:10.1016/j.jalz.2009.04.020
Parsons C. G. Danysz W. Quack G.   (1998 ). Glutamate in CNS disorders
as a target for drug development: An update. 
Drug News Perspect , 11 (9 ),
523 –569 . Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1561666915616669 
Parsons C. G. Stöffler A. Danysz W.   (2007 ). Memantine: A NMDA receptor
antagonist that improves memory by restoration of homeostasis in the
glutamatergic system – Too little activation is bad, too much is even
worse. 
Neuropharmacology , 53 (6 ),
699 –723 .
doi:10.1016/j.neuropharm.2007.07.01317904591 
Peskind E. R. Potkin S. G. Pomara N. Ott B. R. Graham S. M. Olin J. T. McDonald S.   (2006 ). Memantine Treatment in Mild
to Moderate Alzheimer Disease: A 24-Week Randomized, Controlled
Trial. 
Am J Geriatr Psychiatry , 14 (8 ),
704 –715 .
doi:10.1097/01.JGP.0000224350.82719.8316861375 
Petralia R. S. Wang Y.-X. Niedzielski A. S. Wenthold R. J.   (1996 ). The metabotropic glutamate
receptors, MGLUR2 and MGLUR3, show unique postsynaptic, presynaptic and
glial localizations. 
Neuroscience , 71 (4 ),
949 –976 .
doi:10.1016/0306-4522(95)00533-18684625 
Puzzo D. Arancio O.   (2012 ). Amyloid-β peptide: Dr.
Jekyll or Mr. Hyde? 
J Alzheimers Dis , 33 (S1 ),
S111 –S120 .
doi:10.3233/JAD-2012-129033
Puzzo D. Privitera L. Leznik E. Fa M. Staniszewski A. Palmeri A. Arancio O.   (2008 ). Picomolar amyloid-beta
positively modulates synaptic plasticity and memory in
hippocampus . J Neurosci ,
28 (53 ),
14537 –14545 .
doi:10.1523/JNEUROSCI.2692-08.200819118188 
Quintero J. E. Pomerleau F. Huettl P. Johnson K. W. Offord J. Gerhardt G. A.   (2011 ). Methodology for rapid
measures of glutamate release in rat brain slices using ceramic-based
microelectrode arrays: Basic characterization and drug
pharmacology. 
Brain Res , 1401 ,
1 –9 .
doi:10.1016/j.brainres.2011.05.02521664606 
Rammes G. Hasenjäger A. Sroka-Saidi K. Deussing J. M. Parsons C. G.   (2011 ). Therapeutic significance of
NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors
in mediating the synaptotoxic effects of β-amyloid oligomers on long-term
potentiation (LTP) in murine hippocampal slices. 
Neuropharmacology , 60 (6 ),
982 –990 .
doi:10.1016/j.neuropharm.2011.01.05121310164 
Reisberg B. Doody R. Stöffler A. Schmitt F. Ferris S. Möbius H. J.   (2003 ). Memantine in
moderate-to-severe Alzheimer’s disease. 
N Engl J Med , 348 (14 ),
1333 –1341 .
doi:10.1056/NEJMoa01312812672860 
Revett T. J. Baker G. B. Jhamandas J. Kar S.   (2013 ). Glutamate system, amyloid ß
peptides and tau protein: Functional interrelationships and relevance to
Alzheimer disease pathology. 
J Psychiatry Neurosci , 38 (1 ),
6 –23 . doi:10.1503/jpn.11019022894822 
Riedel G.   (1996 ). Function of metabotropic
glutamate receptors in learning and memory . Trend
Neurosci , 19 (6 ),
219 –223 .
doi:10.1016/0166-2236(96)20012-88761955 
Robinson S. R.   (2001 ). Changes in the cellular
distribution of glutamine synthetase in Alzheimer’s disease. 
J Neurosci Res , 66 ,
972 –980 .
doi:10.1002/jnr.1005711746426 
Rodríguez-Arellano J. J. Parpura V. Zorec R. Verkhratsky A.   (2016 ). Astrocytes in physiological
aging and Alzheimer’s disease. 
Neuroscience , 323 ,
170 –182 .
doi:10.1016/j.neuroscience.2015.01.00725595973 
Rodriguez-Perdigon M. Tordera R. M. Gil-Bea F. J. Gerenu G. Ramirez M. J. Solas M.   (2016 ). Down-regulation of
glutamatergic terminals (VGLUT1) driven by Aβ in Alzheimer’s
disease. 
Hippocampus , 26 (10 ),
1303 –1312 .
doi:10.1002/hipo.2260727258819 
Rudy C. C. Hunsberger H. C. Weitzner D. S. Reed M. N.   (2015 ). The role of the tripartite
glutamatergic synapse in the pathophysiology of Alzheimer’s
disease. 
Aging Dis , 6 (2 ),
131 –148 .
doi:10.14336/AD.2014.042325821641 
Rupsingh R. Borrie M. Smith M. Wells J. L. Bartha R.   (2011 ). Reduced hippocampal
glutamate in Alzheimer disease. 
Neurobiol Aging , 32 ,
802 –810 .
doi:10.1016/j.neurobiolaging.2009.05.00219501936 
Sattler R. Xiong Z. Lu W. Y. Hafner M. MacDonald J. F. Tymianski M.   (1999 ). Specific coupling of NMDA
receptor activation to nitric oxide neurotoxicity by PSD-95
protein. 
Science (New York, N.Y.) ,
284 (5421 ),
1845 –1848 .
doi:10.1126/SCIENCE.284.5421.1845
Schallier A. Smolders I. Van Dam D. Loyens E. De Deyn P. P. Michotte A. Massie A.   (2011 ). Region- and age-specific
changes in glutamate transport in the AβPP23 mouse model for Alzheimer’s
disease. 
J Alzheimers Dis , 24 (2 ),
287 –300 .
doi:10.3233/JAD-2011-10100521297271 
Schneider L. S. Dagerman K. S. Higgins J. P. T. McShane R.   (2011 ). Lack of evidence for the
efficacy of memantine in mild Alzheimer disease. 
Arch Neurol , 68 (8 ),
991 . doi:10.1001/archneurol.2011.6921482915 
Scott H. A. Gebhardt F. M. Mitrovic A. D. Vandenberg R. J. Dodd P. R.   (2011 ). Glutamate transporter
variants reduce glutamate uptake in Alzheimer’s disease .
Neurobiol Aging , 32 (3 ),
553.e1–553.e11.
doi:10.1016/j.neurobiolaging.2010.03.008
Selkoe D. J.   (2002 ). Alzheimer’s disease is a
synaptic failure. 
Science , 298 (5594 ),
789 –791 .
doi:10.1126/science.107406912399581 
Selkoe D. J.   (2008 ). Soluble oligomers of the amyloid β-protein:
Impair synaptic plasticity and behavior. Behav Brain Res,
192(1), 106–113. doi:10.1007/978-3-540-76330-7_8
Serrano F. Klann E.   (2004 ). Reactive oxygen species and
synaptic plasticity in the aging hippocampus. 
Ageing Res Rev , 3 (4 ),
431 –443 .
doi:10.1016/J.ARR.2004.05.00215541710 
Shankar G. M. Li S. Mehta T. H. Garcia-Munoz A. Shepardson N. E. Smith I. Brett F. M. Farrell M. A. Rowan M. J. Lemere C. A. Regan C. M. Walsh D. M. Sabatini B. L. Selkoe D. J.   (2008 ). Amyloid-β protein dimers
isolated directly from Alzheimer’s brains impair synaptic plasticity and
memory. 
Nat Med , 14 (8 ),
837 –842 . doi:10.1038/nm178218568035 
Shelat P. B. Chalimoniuk M. Wang J.-H. Strosznajder J. B. Lee J. C. Sun A. Y. Simonyi A. Sun G. Y.   (2008 ). Amyloid beta peptide and
NMDA induce ROS from NADPH oxidase and AA release from cytosolic
phospholipase A2 in cortical neurons. 
J Neurochem , 106 (1 ),
45 –55 .
doi:10.1111/j.1471-4159.2008.05347.x18346200 
Shie F.-S. LeBoeuf R. C. Jin L.-W. LeBoeur R. C.   (2003 ). Early intraneuronal Abeta
deposition in the hippocampus of APP transgenic mice. 
Neuroreport , 14 (1 ),
123 –129 .
doi:10.1097/01.wnr.0000051151.87269.7d12544843 
Šišková Z. Justus D. Kaneko H. Friedrichs D. Henneberg N. Beutel T. Pitsch J. Schoch S. Remy S.   (2014 ). Dendritic structural
degeneration is functionally linked to cellular hyperexcitability in a mouse
model of Alzheimer’s disease. 
Neuron , 84 (5 ),
1023 –1033 .
doi:10.1016/J.NEURON.2014.10.02425456500 
Snyder E. M. Nong Y. Almeida C. G. Paul S. Moran T. Choi E. Y. Nairn A. C. Salter M. W. Lombroso P. J. Gouras G. K. Greengard P.   (2005 ). Regulation of NMDA receptor
trafficking by amyloid-β. 
Nat Neurosci , 8 (8 ),
1051 –1058 . doi:10.1038/nn150316025111 
Sokolow S. Luu S. H. Nandy K. Miller C. A. Vinters H. V. Poon W. W. Gylys K. H.   (2012 ). Preferential accumulation of
amyloid-beta in presynaptic glutamatergic terminals (VGluT1 and VGluT2) in
Alzheimer’s disease cortex. 
Neurobiol Dis , 45 (1 ),
381 –387 .
doi:10.1016/j.nbd.2011.08.02721914482 
Streit W. J. Mrak R. E. Griffin W. S. T.   (2004 ). Microglia and
neuroinflammation: A pathological perspective . J
Neuroinflammation , 1 (1 ),
14 . doi:10.1186/1742-2094-1-1415285801 
Stutzmann G. E.   (2005 ). Calcium dysregulation, IP3
signaling, and Alzheimer’s disease. 
Neuroscientist , 11 (2 ),
110 –115 .
doi:10.1177/107385840427089915746379 
Takamori S. Rhee J. S. Rosenmund C. Jahn R.   (2000 ). Identification of a
vesicular glutamate transporter that defines a glutamatergic phenotype in
neurons. 
Nature , 407 (6801 ),
189 –194 . doi:10.1038/3502507011001057 
Takumi Y. Ramírez-León V. Laake P. Rinvik E. Ottersen O. P.   (1999 ). Different modes of
expression of AMPA and NMDA receptors in hippocampal
synapses. 
Nat Neurosci , 2 (7 ),
618 –624 . doi:10.1038/1017210409387 
Talantova M. et al  (2013 
). Aβ induces astrocytic glutamate release, extrasynaptic NMDA
receptor activation, and synaptic loss. 
Proc Natl Acad Sci U S A .,
110 (27 ),
E2518 –E2527 .
doi:10.1073/pnas.130683211023776240 
Thal D. R. Rüb U. Schultz C. Sassin I. Ghebremedhin E. Del Tredici K. Braak E. Braak H.   (2000 ). Sequence of Abeta-protein
deposition in the human medial temporal lobe. 
J Neuropathol Exp Neurol ,
59 (8 ), 733 –748 .
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10952063; https://academic.oup.com/jnen/article-abstract/59/8/733/261006510952063 
Tully T. Bourtchouladze R. Scott R. Tallman J.   (2003 ). Targeting the CREB pathway
for memory enhancers. 
Nat Rev Drug Discov , 2 (4 ),
267 –277 . doi:10.1038/nrd106112669026 
Tyszkiewicz J. P. Yan Z.   (2005 ). β-Amyloid peptides impair
PKC-dependent functions of metabotropic glutamate receptors in prefrontal
cortical neurons. 
J Neurophysioly , 93 (6 ),
3102 –3111 .
doi:10.1152/jn.00939.2004
Um J. W. Kaufman A. C. Kostylev M. Heiss J. K. Stagi M. Takahashi H. Kerrisk M. E. Vortmeyer A. Wisniewski T. Koleske A. J. Gunther E. C. Nygaard H. B. Strittmatter S. M.   (2013 ). Metabotropic glutamate
receptor 5 is a coreceptor for Alzheimer Aβ oligomer bound to cellular prion
protein. 
Neuron , 79 (5 ),
887 –902 .
doi:10.1016/J.NEURON.2013.06.03624012003 
Valladolid-Acebes I. Merino B. Principato A. Fole A. Barbas C. Lorenzo M. P. García A. Del Olmo N. Ruiz-Gayo M. Cano V.   (2012 ). High-fat diets induce
changes in hippocampal glutamate metabolism and
neurotransmission. 
Am J Physiol Endocrinol Metab ,
302 (4 ),
E396 –E402 .
doi:10.1152/ajpendo.00343.201122114023 
Van Dam D. Abramowski D. Staufenbiel M. De Deyn P. P.   (2005 ). Symptomatic effect of
donepezil, rivastigmine, galantamine and memantine on cognitive deficits in
the APP23 model. 
Psychopharmacology , 180 (1 ),
177 –190 .
doi:10.1007/s00213-004-2132-z15654502 
Verkhratsky A. Kirchhoff F.   (2007 ). Glutamate-mediated
neuronal-glial transmission. 
J Anat , 210 (6 ),
651 –660 .
doi:10.1111/j.1469-7580.2007.00734.x17504269 
Verkhratsky, A., Olabarria, M.,
Noristani, H. N., Yeh, C., Rodriguez, J. J. (2010). Astrocytes in Alzheimer’s
Disease. Neurotherapeutics, 7(4), 399–412.
doi:10.1016/j.nurt.2010.05.017
von Engelhardt J. Coserea I. Pawlak V. Fuchs E. C. Köhr G. Seeburg P. H. Monyer H.   (2007 ). Excitotoxicity in vitro by
NR2A- and NR2B-containing NMDA receptors. 
Neuropharmacology , 53 (1 ),
10 –17 .
doi:10.1016/J.NEUROPHARM.2007.04.01517570444 
Walsh D. M. Klyubin I. Fadeeva J. V. Cullen W. K. Anwyl R. Wolfe M. S. Rowan M. J. Selkoe D. J.   (2002 ). Naturally secreted oligomers
of amyloid β protein potently inhibit hippocampal long-term potentiation in
vivo. 
Nature , 416 (6880 ),
535 –539 . doi:10.1038/416535a11932745 
Wang H.-W. Pasternak J. F. Kuo H. Ristic H. Lambert M. P. Chromy B. Viola K.L. Klein W.L. Trommer B. L.   (2002 ). Soluble oligomers of β
amyloid (1-42) inhibit long-term potentiation but not long-term depression
in rat dentate gyrus. 
Brain Res , 924 (2 ),
133 –140 .
doi:10.1016/S0006-8993(01)03058-X11750898 
Wang H. Y. Lee D. H. D’Andrea M. R. Peterson P. A. Shank R. P. Reitz A. B.   (2000 a). Beta-amyloid(1-42) binds to
alpha7 nicotinic acetylcholine receptor with high affinity. Implications for
Alzheimer’s disease pathology . J Biol Chem ,
275 (8 ),
5626 –5632 . Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1068154510681545 
Wang H. Y. Lee D. H. S. Davis C. B. Shank R. P.   (2000 b). Amyloid peptide Aβ1-42
binds selectively and with picomolar affinity to α7 nicotinic acetylcholine
receptors. 
J Neurochem , 75 (3 ),
1155 –1161 .
doi:10.1046/j.1471-4159.2000.0751155.x10936198 
Wang Q. Walsh D. M. Rowan M. J. Selkoe D. J. Anwyl R.   (2004 ). Block of long-term
potentiation by naturally secreted and synthetic amyloid-peptide in
hippocampal slices is mediated via activation of the kinases c-Jun
N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated
protein kinase as well as metabotropic glutamate receptor type
5. 
J Neurosci , 24 (13 ),
3370 –3378 .
doi:10.1523/JNEUROSCI.1633-03.200415056716 
Welsby P. Rowan M. Anwyl R.   (2006 ). Nicotinic receptor-mediated
enhancement of long-term potentiation involves activation of metabotropic
glutamate receptors and ryanodine-sensitive calcium stores in the dentate
gyrus. 
Eur J Neurosci , 24 (11 ),
3109 –3118 .
doi:10.1111/j.1460-9568.2006.05187.x17156372 
West M. J. Coleman P. D. Flood D. G Troncoso J. C.   (1994 ). Differences in the pattern
of hippocampal neuronal loss in normal ageing and Alzheimer’s
disease. 
Lancet , 344 (8925 ),
769 –772 .
doi:10.1016/S0140-6736(94)92338-87916070 
Wilcox K. C. Lacor P. N. Pitt J. Klein W. L.   (2011 ). Aβ oligomer-induced synapse
degeneration in Alzheimer’s disease. 
Cell Mol Neurobiol , 31 (6 ),
939 –948 .
doi:10.1007/s10571-011-9691-421538118 
Williams C. Mehrian Shai R. Wu Y. Hsu Y.-H. Sitzer T. Spann B. McCleary C. Mo Y. Miller C. A.   (2009 ). Transcriptome analysis of
synaptoneurosomes identifies neuroplasticity genes overexpressed in
incipient Alzheimer’s disease. 
PloS One , 4 (3 ),
e4936 . doi:10.1371/journal.pone.000493619295912 
Winblad B. Jones R. W. Wirth Y. Stöffler A. Möbius H. J.   (2007 ). Memantine in moderate to
severe Alzheimer’s disease: A meta-analysis of randomised clinical
trials. 
Dement Geriatr Cogn Disord ,
24 (1 ), 20 –27 .
doi:10.1159/00010256817496417 
Winblad B. Poritis N.   (1999 ). Memantine in severe
dementia: Results of the9M-best study (benefit and efficacy in severly
demented patients during treatment with memantine). 
Int J Geriatr Psychiatry ,
14 (2 ), 135 –146 .
doi:10.1002/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-010885864 
Wisden W. Seeburg P. H.   (1993 ). Mammalian ionotropic
glutamate receptors. 
Curr Opin Neurobiol , 3 (3 ),
291 –298 .
doi:10.1016/0959-4388(93)90120-N8396474 
Xiong W.-X. Zhou G.-X. Wang B. Xue Z.-G. Wang L. Sun H.-C. Ge S.-J.   (2013 ). Impaired spatial learning
and memory after sevoflurane–nitrous oxide anesthesia in aged rats is
associated with down-regulated cAMP/CREB signaling. 
PLoS One , 8 (11 ),
e79408 . doi:10.1371/journal.pone.007940824260214 
Yamin G.   (2009 ). NMDA receptor-dependent
signaling pathways that underlie amyloid β-protein disruption of LTP in the
hippocampus. 
J Neurosci Res , 87 (8 ),
1729 –1736 .
doi:10.1002/jnr.2199819170166 
Yasuda R. P. Ikonomovic M. D. Sheffield R. Rubin R. T. Wolfe B. B. Armstrong D. M.   (1995 ). Reduction of AMPA-selective
glutamate receptor subunits in the entorhinal cortex of patients with
Alzheimer’s disease pathology: A biochemical study .
Brain Res , 678 (1–2 ).
doi:10.1016/0006-8993(95)00178-S
Yin J. C. Tully T.   (1996 ). CREB and the formation of
long-term memory. 
Curr Opin Neurobiol , 6 (2 ),
264 –268 .
doi:10.1016/S0959-4388(96)80082-18725970 
Young K. F. Pasternak S. H. Rylett R. J.   (2009 ). Oligomeric aggregates of
amyloid β peptide 1–42 activate ERK/MAPK in SH-SY5Y cells via the α7
nicotinic receptor. 
Neurochem Int , 55 (8 ),
796 –801 .
doi:10.1016/j.neuint.2009.08.00219666073 
Zhang L. Jin C. Lu X. Yang J. Wu S. Liu Q. Chen R. Bai C. Zhang D. Zheng L. Du Y. Cai Y.   (2014 ). Aluminium chloride impairs
long-term memory and downregulates cAMP-PKA-CREB signalling in
rats. 
Toxicology , 323 ,
95 –108 .
doi:10.1016/J.TOX.2014.06.01124973631 
Zhang Y. Li P. Feng J. Wu M.   (2016 ). Dysfunction of NMDA
receptors in Alzheimer’s disease. 
Neurol Sci , 37 (7 ),
1039 –1047 .
doi:10.1007/s10072-016-2546-526971324

